

**STUDIES ON THE LEAVES OF *Punica granatum* LINN.  
AND ITS INVITRO INHIBITION OF AChE FOR POTENTIAL  
USE IN ALZHEIMER'S TREATMENT**

***Dissertation submitted to***

***The Tamilnadu Dr. M.G.R. Medical University, Chennai  
In partial fulfillment of the requirement for the award of Degree of***

**MASTER OF PHARMACY**



**MARCH – 2009**

**DEPARTMENT OF PHARMACOGNOSY  
COLLEGE OF PHARMACY  
MADURAI MEDICAL COLLEGE  
MADURAI – 625 020.**

Dr. (Mrs.) L. Suseela, M.Pharm., Ph.D.,  
Principal,  
Professor & Head, Department of Pharmacognosy  
College of Pharmacy,  
Madurai Medical College,  
Madurai – 625 020.

---

## CERTIFICATE

This is to certify that the dissertation entitled “**Studies on the leaves of *Punica granatum*, Linn and its invitro inhibition of AChE for Potential use in Alzheimer’s treatment**” was done by **Mr. N. Ramasamy**, in Department of Pharmacognosy, Madurai Medical College, Madurai – 20, in partial fulfillment of the requirement for the Degree of Master of Pharmacy in Pharmacognosy. This dissertation is forwarded to the Controller of Examination, The Tamilnadu Dr. M.G.R. Medical University, Chennai.

Station :

(Dr. L. SUSEELA)

Date :

## ACKNOWLEDGEMENT

### **“I Owe to the helping hands of the almighty”**

Indeed my project is a small work done with the help of primitive persons at heart. So, it is my bounded duty to promulgate them individually.

I am very thankful to **Dr.(Mrs.) L. Suseela M.Pharm, Ph.D.**, Principal, College of Pharmacy, Madurai Medical College, Madurai for her excellent encouragement, guidance, boundless enthusiasm, motivation and valuable advice for the successful completion of this work.

Any work of this nature needs the help of many heads and hands. The efficient, friendly, cheerful guidance of **Mr. K. Periyamayagam, M.Pharm., P.G.Diploma in Clinical Pharmacy (Australia), (Ph.D.)**, Assistant Reader, Department of Pharmacognosy, Madurai Medical College, Madurai, have done much to improve and complete this work. I record my heartfelt thanks to him for his enthusiastic co-operation as my project guide and for all the constant encouragement, suggestions, contribution and support rendered during the project work. Further, I find no words to exhibit my gratitude to my guide.

I would like to express my deep and sincere gratitude to **Dr. Mohammed Majeed**, Chairman, Sami Labs Ltd., Bangalore, for permitting me to utilize the facilities to carryout this dissertation.

I wish to express my warm and sincere thanks to **Dr. G. Vasudeva Kamath, Ph.D., Scientist R & D** for his detailed and constructive comments, precious guidance and for his important support throughout this work.

I especially want to thank **Mrs. Geetha. K.G., M.Sc., Head R & D (Biological), Dr. S. Natarajan, Ph.D., Head, Dr. D. Suresh Kumar, Ph.D., Senior Scientist, Dr. Muthuraman, Ph.D., R & D (Phytochemistry)** and all Staff Members **Dr. Indu Bala Koul, Ms. Susmitha Anand, Dr. Pritee Paliwal, Mrs. Flitty Jojo, Mrs. Soumya Jacob, Mr. Renjith Mahesenan, Mrs. T.Y. Meghana, Mrs. Priyanka. G, Ms. V.S. Misha,(MSc.,) Mr. K.H. Gangaiah** in the department of Biological Research for their overwhelming enthusiasm and integral view on research and their mission for providing “only high quality work and not less”, has inspired and motivated me to involve in this work.

I wish to place on record here my indebtedness and heartfelt thanks to **Ms. R. Gowri. (M.Pharm), Mr. T. Venkatarathinakumar, M.Pharm. (Ph.D.)** Assistant Readers, Department of Pharmacognosy, Madurai Medical College, Madurai.

I extend my special thanks to **Mrs. A. Sethuramani, M.Pharm (Ph.D.) and Mrs. A. Krishnaveni, M.Pharm (Ph.D.), Tutors** in Department of Pharmacognosy for helping me to carry out my work.

I extend my sincere thanks to Lab supervisor **Mrs. C. K. Abarna DMLT, Mrs. S. Revathy, DMLT**, Lab technicians, and **Mrs. P. Ellayi, Attender**, Department of Pharmacognosy, Madurai Medical College, Madurai for their help during this work.

I especially want to thank my **Mrs. B. Uma maheshwari, Mrs. K. Chitradevi, Miss. M. Sangami Bharathi** for their valuable suggestions and kind co-operation during this work. I am really glad that I have come to get know them in my life.

I would also like to express my heartfelt thanks to **G. Sathyabalan, P. Senniapan, M. Sharmilabanu, S. Swarnakumari**, 1<sup>st</sup> M.Pharm, for without whose co-operation this work would not have seen the light of the day.

I extend my thanks to **Dr. A. Sadasakthi, Ph.D.**, Professor and Head, Department of Horticulture, Tamilnadu Agricultural University, Madurai for identification and collection of this plant.

It gives me an immense pleasure to thank **Post graduate students of Department of Pharmaceutical Chemistry and Pharmaceutics**, Madurai Medical College for their kind co-operation in carrying out my dissertation work.

I will have long lasting gratitude and special word of thanks to **Mr. M. Ismail, M.Sc**, Senior Entomologist for his timely selfless helps, excellent encouragement and valuable suggestions rendered during this project work.

I extend my special thanks to **Prof. P. Jayaraman, Ph.D.**, Director (PARC), Chennai for his help regarding the microscopy of this plant.

I extend my sincere thanks to **Mr. S. Mahalingam, Mrs. R. Anitha, Mr. Tamizh Selvan, Ms. M. Munieswari, Ms. Jasmine, Ms. Dhana Lakshmi** of Venus Computers, Goripalayam, Madurai for their time bound help in typing and completion of this work.

Last but not least, thanks are to God for my life through all tests in the past two years. Lord, You have made my life more beautiful. May your name be exalted, honoured and glorified.

# CONTENTS

Chapter	Title	Page No.
I.	Introduction	1
II.	Review of Literature	12
III.	Aim and Objective	37
IV.	Pharmacognostic Studies:	39
	<i>Section – A</i> : Macroscopy of <i>P. granatum</i>	39
	<i>Section – B</i> : Microscopical study of leaf of <i>P. granatum</i>	44
	<i>Section – C</i> : Qualitative microscopy for leaves of <i>P. granatum</i>	50
V.	Phytochemical Studies:	58
	<i>Section – A</i> : Phytochemical studies for the leaf of <i>P. granatum</i>	58
	<i>Section – B</i> : TLC & HPLC – analysis for various extracts of leaves of <i>P. granatum</i>	71
VI.	Acute toxicological study	78
VII.	Pharmacological Screening:	81
	<i>Section – A</i> : Standardization and Validation of AChE Assay	86
	<i>Section – B</i> : Screening of samples for AChE Inhibitory activity	95
VIII.	Results and Discussion	100
IX.	Conclusion	113
	References	

## LIST OF TABLES

Table No.	Title	Page No.
1.	Vein islet and vein termination number for leaves of <b><i>P.granatum</i></b>	51
2.	Stomatal Number for leaves of <b><i>P. granatum</i></b>	52
3.	Stomatal Index for leaves of <b><i>P. granatum</i></b>	53
4.	Ash values for leaves of <b><i>P. granatum</i></b>	55
5.	Loss on drying for leaves of <b><i>P. granatum</i></b>	56
6.	Extractive values for leaves of <b><i>P. granatum</i></b> (successive solvents)	57
7.	Response to the preliminary Phytochemical screening for crude powder of <b><i>P. granatum</i></b>	69
8.	Response to the preliminary Phytochemical screening for various extracts of <b><i>P. granatum</i></b>	70
9.	TLC of different extracts of leaves of <b><i>P. granatum</i></b>	73
10.	HPLC profile of various extracts of leaves of <b><i>P. granatum</i></b>	77
11.	Effect of various concentration of chloroform extract from leaves of <b><i>P. granatum</i></b> on <b><i>Artemia nauplii</i></b> .	80
12.	Standardization of AChE enzyme concentration	86
13.	Effect of different concentration of enzyme in AChE activity	87
14.	Standardization of substrate concentration	88
15.	Effect of different concentration of substrate in AChE activity	89
16.	Standardization of Ellman reagent concentration	91
17.	Effect of different concentration of Ellman reagent in AChE activity	92



<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
18.	Estimation of pH maxima	93
19.	Effect of pH in AChE activity	93
20.	Estimation of temperature maxima	94
21.	Effect of temperature in AChE activity	94
22.	Estimation of AChE inhibitory activity for Tacrine and Ursolic acid	95
23.	Effect of different concentration of Ursolic acid in AChE inhibition	96
24.	Effect of different concentration of Tacrine in AChE inhibition	96
25.	Sigmoidal dose response for Ursolic acid and Tacrine	97
26.	Effect of different concentration of various extracts in AChE inhibition	98
27.	Sigmoidal dose response for various extracts in AChE inhibition	98
28.	Comparison of IC <sub>50</sub> value and percentage inhibition of standard and extracts in AChE inhibition.	99

## INTRODUCTION

Man's existence on this earth has been made possible only because of the vital role played by the plant kingdom in sustaining his life. Without the variety of living organism that makes up the world of plants, animal life would not survive and our planet would have been a barren and life less world of deserts<sup>1</sup>.

Plants are the only economic source of a number of well established and important drugs. In addition they are the source of some chemical intermediates needed for the production of a number of drugs<sup>2</sup>.

### **Medicinal plants global view**

The universal role of plants in the treatment of disease is exemplified by their employment in all the major systems of medicine. There is a great wealth of knowledge concerning the medicinal, narcotic and other properties of plants that is still transmitted from generation to generation to tribal societies. The knowledge of tribal (folk) medicines are enormous but has been lying dormant due to various reasons and is worthy exploration<sup>3</sup>.

By studying the folk medicine not only the Materia Medica of different systems will be enriched, but the economic status of the country will also become sound. As the medicinal plants are considered the natural wealth of the country, for internal consumption as well as for earning valuable foreign exchange<sup>4</sup>.

## **WHO views on Medicinal Plants**

The world health organization has estimated that nearly 80% of the population of the developing countries meet their primary health care needs through plant based traditional medicine. Towards the end of the 20<sup>th</sup> century there began a revival of interest in traditional medicine not only in developing countries, but also in the developed countries. The revival of interest in herbal drugs started mainly because of the widespread belief that green medicine is healthier than synthetic products. Now the increasing popularity of plant – based drugs are felt all over the world leading to fast growing market for herbal drugs, pharmaceuticals, nutraceuticals, functional foods and even cosmetics<sup>5</sup>.

## **Status of India**

India has an ancient heritage of traditional medicine, perhaps largest producer of medicinal herbs and is rightly called **“THE BOTANICAL GARDEN OF THE WORLD”**. Medicinal herbs have been in use for thousand of years, in one form to another under the indigenous system of medicine<sup>6</sup>.

India was one of the pioneers in the development and practice of well documented indigenous systems of medicine, particularly Ayurvedha, Siddha and Unani. The Indian population has depend on mostly plant based crude drugs for the treatment of various ailments. Medicinal plants

sector has traditionally occupied an important position in the socio-cultural, spiritual and medicine arena of rural and tribal lives of Tamil Nadu.

### **Contribution by Tamil Nadu**

Siddha system is one of the ancient traditional systems of medicine in India. Siddhars, the spiritual scientists of Tamil Nadu are the founders of the scientific system. The basic concept of siddha of medicine is

**“Food is medicine; Medicine is food”.**

Saint Thiruvalluvar says,

***“Miginum kuraiyinum noiseyyum noolar***

***Vali mudhala enniya moondru”.***

“Wind, bile, phlegm three causes diseases

So doctors deem it more or less”

And regarding diagnosis,

***“Noi naadi noimudhal naadi athuthanikum***

***Vaai naadi vayppa seyal”***

“Test disease, it’s causes and cure

And apply remedy that is sure”<sup>7</sup>.

### **Modern Medicine – Demerits**

Inspite of tremendous advances made in the modern system of medicine there are still a large number of conditions for which suitable drugs are not available in the modern system of medicine and thus, we

should denote, time, efforts, and found in those areas where new drugs are urgently needed and such areas include tropical diseases, rheumatic diseases, viral infection, liver disease, bronchial asthma, diabetes, immunomodulators as adjuvant for chemotherapy and adaptogens<sup>8</sup>.

### **Natural products for modern medicine**

Plants have been used for medicine from the time immemorial because they have fitted the immediate personal need, are easily accessible and inexpensive. Researchers have no doubt that nature is still the preeminent synthetic chemist and that in plants particularly, there are almost infinite reserves of fascinating chemical constituents with actual and potential effects on the human body.

Plant products can also be useful as starting material for the semi synthetic preparation of other drugs. The main examples are plant steroids hormones. Natural products continue to form a significant proportion of drugs in current use and of those under investigation. It has been estimated that 56% of the lead compounds for medicinal in the British National Formulary are natural products or are derived from natural products.

Natural products will continue to be important in three areas of drug discovery.

1. As targets for production by biotechnology.
2. As a source of new lead compounds of novel chemical structure.
3. As the active ingredients of useful treatments derived from traditional systems of medicine<sup>9</sup>.

### **Priorities in Medicinal plant research**

The plant kingdom represents as enormous reservoir of biologically active molecules and so far only a small fraction of plants with medicinal activity has been assayed. Nearly 50% drugs used in medicine are of plant origin.

There is therefore much current research devoted to the phytochemical investigation of higher plants which have ethnobotanical information associated with them.

The phytochemical isolated are then screened for different type of biological activity.

The crude plants extracts can be first assayed for particular activities and the active fraction then assayed phytochemically<sup>10</sup>.

### **Phytonutrients – The Natural Drugs of the Future**

#### **Degenerative Diseases**

Many advances in the diagnosing of diseases and the discovery of a myriad of new names to diseases has occurred, the battle to increase

quality of life and the overcoming, curing and proper treatment of **degenerative diseases** has been all but lost. Allopathic medicine has not changed its treatment of cancer in over 40 years. Though new drugs keep popping up, the results are still the same and the most effective treatment for cancer is still surgery. Heart disease, diabetes, arthritis, leukemia, **Alzheimer's**, Parkinson's, Hodgkin's and dozens of other disease names strike fear into our minds and as we age, many of us contemplate... ". Which one will take me from this life and how will I fight it?" Today with the current standard of allopathic medicine it is only a matter of time before you are beaten by one of the many known or even unknown degenerative diseases. There are no known cures to any of these degenerative diseases.

Currently your only option is a long list of prescription drugs that may alleviate symptoms but slowly eat away your body's immunity and quality of life.

There is hope however. For more than 20 years now scientists have been researching plants and discoveries made within the last 15 years may hold some of the answers to combating many of the degenerative diseases<sup>11,12</sup>.

### **Alzheimer's disease**

Alzheimer's disease (AD), also called Alzheimer disease or simply Alzheimer's, is the most common type of dementia. Alzheimer's is a degenerative and terminal disease for which there is no known cure. In its

most common form, it afflicts individuals over 65 years old, although a less prevalent early onset form also exists. It is estimated that 26.6 million people worldwide were afflicted by AD in 2006, which could quadruple by 2050, although estimate very greatly. The disease was first described by Alois Alzheimer.

### **Symptoms of AD**

In the early stages, the most commonly recognized symptom is memory loss, such as the difficulty to remember recently learned facts. Earlier occurring symptoms are often mistaken as being noncritical age – related complaints, or forms of stress. As the disease advances symptoms include confusion, anger, mood swings, language breakdown, long – term memory loss, and the general withdrawal of the sufferer as his or her senses decline. Gradually, minor and major bodily functions are lost, leading ultimately to death.

The cause and progression of Alzheimer's disease are not well understood.

### **Characteristics of AD**

The disease course is divided into four stages, with a progressive pattern of cognitive and functional impairment expressed from one stage to the next.

1. Pre dementia
2. Early dementia



3. Moderate dementia

4. Advanced

Three major competing hypothesis exist to explain the cause of the disease are

1. Cholinergic hypothesis (Selective neuronal loss)

2. Amyloid hypothesis (Senile plaques)

3. Tau protein hypothesis (Neurofibrillary tangles)

### **Current Treatment**

Four medications, to treat the cognitive manifestations of AD, are currently approved by regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Three are acetylcholinesterase inhibitors and the other is memantine, an NMDA receptor antagonist. No drug has an indication for delaying or halting the progression of the disease.

The recent development of new AChE inhibitors as drugs capable of reducing the symptoms of AD. Examples – tacrine, donepezil, galanthamine, rivastigmine through inhibition of the enzyme acetylcholinesterase, responsible for breakdown of acetyl choline in the neural synapse<sup>13</sup>.

Although very few drugs are currently approved by regulatory authorities for treating multi – factorial ailments and disorders of cognition such as Alzheimer’s disease, certain plant – derived agents including, for

example, galantamine (from *Galanthus nivalis* L.) and rivastigmine (a semi – synthetic derivative of physostigmine) are finding an application in modern medicine. However, in Ayurveda, the Indian traditional system of medicine, which is more than 5000 years old, selected plants have long been classified as ‘medhya rasayanas’ from the Sanskrit words “medhya”, meaning intellect or cognition and rasayana”, meaning “rejuvenation”. These plants are used both in herbal and conventional medicine and offer benefits that pharmaceutical drugs lack<sup>14</sup>.

However, these drugs are known to have limitations for clinical use due to their short half lives and /or unfavorable side effects (elevated transaminase, nausea, vomiting, diarrhoea, dyspepsia and etc)<sup>15</sup>.

So, it is necessary to search for AChE inhibitors with lower side effects from natural resources.

### List of medicinal plants having AChE inhibition

Plant Name	Phytoconstituent
<i>Galanthus nivalis</i>	- Galanthamine <sup>14</sup>
<i>Corydalis ternata</i>	- Protopine <sup>16</sup>
<i>Origanum majorana</i>	- Ursolic acid <sup>17</sup>
<i>Salvia (sage) species</i> <i>S. Fruticosa</i> , <i>S. lavandulafolia</i> , <i>S. Officinalis</i> <i>Salvia santolifolia</i>	- Essential oil <sup>18</sup>
<i>Melissa officinalis</i>	- Essential oil <sup>18</sup>
<i>Rosemarinus officinalis</i>	- Essential oil <sup>18</sup>

### Ursolic acid and AChE inhibition

Ursolic acid, also known as urson, prunol, micromerol, and malol, is a pentacyclic triterpenoid compound which naturally occurs in a large number of vegetarian foods, medicinal herbs, and other plants.

Ursolic acid can be used for several pharmacological effects, such as, anti-tumor (skin cancer), hepato protective, anti inflammatory (oral and topical), anti ulcer, anti microbial, anti hyperlipidemic and anti viral. Ursolic acid and its isomer, oleanolic acid both are similar in pharmacological activity.

Ursolic acid inhibits acetylcholinesterase. This the enzyme catalyses the breakdown of the neurotransmitter chemical acetylcholine, which is important for effective cognition and reasoning. The degeneration of acetylcholine – producing neurons in the brains of people with Alzheimer's disease (AD) has been blamed for the symptom of memory loss associated with AD. Thus, sustaining acetylcholine levels may help delay this memory loss<sup>19</sup>.

### **Reason for selection of plant *P. granatum***

In order to find a natural source which has the ursolic acid its one of the phytoconstituents, preliminary literature survey revealed that the leaves of ***Punica granatum*** contains ursolic acid, one of its constituents.

So we planned to investigate the widely available leaves of *P.granatum* belongs to the family punicaceae for its AChE inhibitory activity.

## REVIEW OF LITERATURE

### ENTIRE PLANT

#### Ethnomedical Information

Siang S.T (1983) stated that dried parts of the plant is used for burns in traditional Chinese and Western Medicine as local application<sup>20</sup>.

Jain S.P et al (1984) reported that fresh paste of the plant was used for snakebite as local application<sup>21</sup>.

#### Pharmacognosy

Anonymous (2005) geographical distribution, varieties, cultivation, including soil, propagation, manuring etc have been described in detail<sup>22</sup>.

Shastri V.M et al (1996) determined ashes and mineral content quantitatively by gravimetric and colorimetric methods<sup>23</sup>.

#### Pharmacology

Prakash A.O et al (1986) reported that acetone, methanol and hydro alcoholic extracts showed no embryotoxic effect (200 mg/kg) in pregnant rat by gastric intubation method<sup>24</sup>.

#### Microbiology

Anesini C et al (1993) reported that hot aqueous extract showed antimicrobial activity (62.5 mg/ml) against *E.coli* and *A. niger*<sup>25</sup>.

## **AERIAL PARTS**

### **Pharmacological Activity**

Dhawan B.N et al (1977) reported that hydro alcoholic extract parts of the plant was used as diuretic (0.063 mg/kg), hypothermic (0.125 mg/kg) in rat<sup>26</sup>.

### **Microbiology**

Aynehchi Y et al (1982) reported the antibacterial activity of the ethanolic extact (100 mg/ml) against *P. vulgaris*, *S. paratyphi*, *B. anthracis* by agar plate method<sup>27</sup>.

## **FLOWERS**

### **Ethnomedical Information**

Bellakhar J et al (1991) reported that flowers of the plant was used for diarrhoea in Moroccan pharmacopoeia<sup>28</sup>.

Jafri M.A et al (2000) reported that powdered flower buds was used for bronchitis and diabetes<sup>29</sup>.

Li Y. et al (2005) reported that flowering part was used for diabetes in Unani system of medicine<sup>30</sup>.

Wang R et al (2006) stated that flower was used locally for grey hair of young man in traditional Chinese medicine and also as an astringent, haemostatic<sup>31</sup>.


Bagri P et al (2008) stated that decoction was used as mouthwash in oral and throat inflammation<sup>32</sup>.

Celik I et al (2008) reported that flower is consumed worldwide as beverage<sup>33</sup>.


## Phytochemistry

Batta A.K et al (1973) isolated crystalline chemical components like maslinic acid, asiatic acid<sup>34</sup>.

**ASIATIC ACID**




**MASLINIC ACID**




Kirillova W et al (1988) reported the presence of cyanidine, delphinidine<sup>35</sup>.

Huang T.H et al (2005) identified the presence of **Ursolic acid**, oleanolic acid, gallic acid<sup>36,37</sup>.

**GALLIC ACID**



**ELLAGIC ACID**



Anonymous (2005) mentioned that the presence of pelargonidine 3,5-di glucoside (a light red dye) used for dying cloth<sup>22</sup>.

Wang R et al 2006 reported a new compound pomegranate and six known compounds namely ellagic acid, 3, 3<sup>1</sup>, 4<sup>1</sup> – tri – O – methyl ellagic acid, ethyl brerifolin carboxylate, **Ursolic acid**, masilinic acid and daucosterol<sup>31</sup>.

Jurenka M.T.J et al (2008) reported the presence of **Ursolic acid**, maslinic acid, styptic acid, gallic acid<sup>38</sup>.

## **Pharmacology**

Naqvi A.H et al (1992) stated that the aqueous extract showed antiamoebic activity (25 mg / 10 gm, oral)<sup>39</sup>.

Jafri M.A et al (2000) stated that hydro alcoholic extract showed antidiabetic activity (400 mg/kg, oral) in rats<sup>29</sup>.

Li Y. et al (2005) reported that methanolic extract was active in postprandial hyperglycemia (IC<sub>50</sub> 1.8 mg/ml, oral) in rats<sup>30</sup>.

Wang R et al (2006) reported that conjugate diene inhibition of LDL (0.5 mg/ml, oral)<sup>31</sup>.

Kaur G et al (2006) stated that ethanolic extract of showed antioxidant and hepatoprotective effect (50 – 150 mg/kg, oral) in mice<sup>40</sup>.

Bagri P et al (2008) reported that aqueous extract showed antidiabetic activity, regulation of abnormalities in lipid profiles, oxidative stress (250, 500 mg/kg)<sup>32</sup>.



Celik I et al (2008) reported that flower beverage showed significant improvement in degenerative liver disorder<sup>33</sup>.

## **FRUIT**

### **Ethnomedical Information**

John D et al (1984) stated that tender fruit paste in boiled milk was used in dysentery<sup>41</sup>.

Goh S.H et al (1984) stated that dried fruit was used in child birth disorders in Malaysia<sup>42</sup>.

Arseculeratne S.N et al (1985) stated that fresh fruit aqueous extract was used in dysentery and as a cooling agent<sup>43</sup>.

Singh Y.N et al (1986) reported that fresh fruit was used in cold and running nose<sup>44</sup>.

Caceres A et al (1987) stated that dried fruit aqueous extract was used locally in conjunctivitis, wounds, ulcers, sores, bruises, mouth lesions, stomatitis, leucorrhea, vaginitis<sup>45</sup>.

Nagaraju N et al (1990) stated that immature fruit powder was used in peptic ulcers<sup>46</sup>.

Anonymous (1992) stated that whole fruit powder was used in diarrhoea and as diet<sup>47</sup>.

Ghazanfar S.A et al (1993) stated that fruit was used in anthelmintic and diarrhoea<sup>48</sup>.

Desta B et al (1994) stated that shade dried fruit hydro alcoholic extract was used in fertility control<sup>49</sup>.

Fujita T et al (1995) reported that fruit paste was used locally in hemorrhoids<sup>50</sup>.

Navarro F.M et al (1996) stated that shade dried fruit hulls infusion was used in infectious diseases<sup>51</sup>.

Vazquer F.M et al (1997) stated that dried fruit was used as an astringent, diuretic, digestive<sup>52</sup>.

Lamar A.Z et al (2008) reported that fruit was used in acidosis, dysentery, diarrhoea, helminthiasis, microbial infections, hemorrhage, respiratory pathologies in Cuban traditional Medicine<sup>53</sup>.

### **Pharmacological Activity**

Prakash A.O et al (1976) reported that ethanolic extract showed no abortifacient and embryotoxic effect (200 mg/kg, oral)<sup>54</sup>.

Goh S.H et al (1984) reported uterine stimulant activity (0.3 ml) but not hypotensive effect (0.1 ml)<sup>42</sup>.

Kamboj V.P et al (1988) reported anti implantation effect<sup>55</sup>.

Igea J.M et al (1991) stated allergenic effect<sup>56</sup>.

Desta B (1994) reported that ethanolic extract showed anti implantation effect (1.82 gm/kg, i.g)<sup>49</sup>.

Alkofahi A et al (1999) stated that ethanolic extract showed antiulcer activity (400 mg/kg, i.g) in rats<sup>57</sup>.

Jung S.H et al (2003) reported that methanolic extract showed aldose reductase inhibition effect ( $IC_{50}$ , 0.27 mg/ml)<sup>58</sup>.

Vidal A et al (2003) reported that hydroalcoholic extract showed antiviral activity (0.4 – 1.2 mg/kg, intranasal)<sup>59</sup>.

Okamoto J.M et al (2004) reported antidepressant activity in mice<sup>60</sup>.

Sudeesh S et al (2005) reported that the flavonoid fraction, acetone extract showed antioxidant activity (10 mg/kg, i.g)<sup>61</sup>.

Vinutha B et al (2007) stated that methanolic extract showed no acetylcholinesterase inhibitory (AChE) activity<sup>62</sup>.

Patel C et al (2008) reported that aqueous extract showed no acute and subchronic toxicity (i.p or oral)<sup>63</sup>.

Lamar A.S et al (2008) stated that hydroalcoholic extract showed no genotoxicity<sup>53</sup>.

## **Microbiological Review**

Konowalchuk J et al (1976) reported that aqueous extract showed antiviral activity<sup>64</sup>.

Caceres A et al (1987) reported that ethanolic extract showed no antiyeast and antibacterial activity (30 ml/disc)<sup>45</sup>.

Desta B (1994) reported that acid ethanolic extract showed antiyeast and antibacterial activity (0.2 ml/disc)<sup>49</sup>.

Menezes S et al (2006) reported that hydroalcoholic extract showed antiyeast activity<sup>65</sup>.

Jurenka M.T.J et al (2008) reported that hydroalcoholic extract showed antibacterial (dental plaque) activity<sup>38</sup>.

## **FRUIT JUICE**

### **Ethnomedical Information**

Singh Y.N (1986) stated that fresh fruit juice was used in diarrhoea and jaundice<sup>44</sup>.


Singh V.K et al (1994) stated that fresh fruit juice was used in high fever, with loss of senses<sup>66</sup>.

Khan M.A et al (2006) reported that fresh fruit juice used in anthelminthic, anaemia, diarrhoea, dyspepsia, tonic<sup>67</sup>.


### **Phytochemistry**

Mavlyanov S.M et al (1997) reported the presence of delphinidine, pelargonidine<sup>68</sup>.

#### **DELPHINIDINE**




#### **PELARGONODINE**




Artik N et al (1998) determined the presence of caffeic acid, chlorogenic acid, p – coumaric acid, quinic acid, quercetin, rutin by HPLC<sup>69</sup>.


**RUTIN**




**CHLOROGENIC ACID**




**p-COUMARIC ACID**




**QUINIC ACID**




**CAFFEIC ACID**



**QUERCETIN**



Hernandez F et al (1999) stated the presence of delphinidine, pelargonidine, cyanidine<sup>70</sup>.



Gil M.I et al (2000) stated the presence of punicalagin<sup>71</sup>.

Teresa S.D.P et al (2000) reported catechin, epicatechin, epigallocatechin 3 – gallate<sup>72</sup>.

Poyrazoglu E et al (2002)<sup>73</sup>, Lansky E.P et al (2007)<sup>74</sup>, Jurenka M.T.J (2008)<sup>38</sup>, were reported aliphatic organic acids (citric acid) phenolic compounds (chlorogenic acid) flavonols (quercetin, catechin).

## Pharmacology

Gil M.I et al (2000) reported antioxidant activity<sup>71</sup>.

Aviram M et al (2000) stated antioxidant, antiatherogenic, and platelet aggregation inhibition activity<sup>75</sup>.

Kalpan M et al (2000) reported antioxidant, antiatherogenic, and cholesterol inhibition activity in mice<sup>76</sup>.

Noda Y et al (2002) stated that the ethanolic extract showed superoxide radical scavenging activity<sup>77</sup>.

Kim N.D et al (2002) reported chemopreventive and adjuvant therapy in human breast cancer<sup>78</sup>.

Toi M et al (2003) stated antiangiogenic activity<sup>79</sup>.

Kawaii S et al (2004) reported differentiation promotion effect<sup>80</sup>.

Van Elswijk D.A. et al (2004) reported that crude fermented and unfermented juice showed antiproliferative activity<sup>81</sup>.

Herber D et al (2007) stated antioxidant activity, dietary supplement<sup>82</sup>.

Jurenka M.T.J et al (2008) reported for the treatment of hyperlipidemia, hypertension, prostate cancer, diabetes, atherosclerosis, carotid artery stenosis, **Alzheimer's disease**<sup>38</sup>.

## **FRUIT (PEEL, RIND, PERICARP)**

### **Ethromedical Information**

Latorre D.L et al (1977) stated that aqueous extract used in menstrual disorder<sup>83</sup>.

Singh Y.N et al (1986) reported that aqueous extract used in diabetes<sup>44</sup>.

Mascolo N et al (1987) reported that aqueous extract showed anti inflammatory activity<sup>84</sup>.

Bellakhdar J et al (1991) stated that pericarp used as an antiulcer, hypoglycemiant, G.I disorder and also as vaginal antiseptic as local application<sup>28</sup>.

Heinrich M et al, reported its use in G.I disorders<sup>85</sup>.

Pillai N.R. et al (1992) was reported antidiarrhoeal activity<sup>86</sup>.

Defeo V et al (1992) stated that decoction used as an astringent, anthelmintic, febrifuge<sup>87</sup>.

Bhattarai N.K et al (1993) stated that decoction used in diarrhoea, dysentery<sup>88</sup>.

Perez C et al (1994) stated that decoction used in urinary and respiratory tract infections<sup>89</sup>.



Alkofalhi A et al (1996), Ahmed I et al (2001) were reported that infusion used in diarrhoea, dysentery<sup>90</sup>.

Sudeesh S et al (2003) reported that pericarp used for diarrhoea, dysentery, stomachic, colitis, piles, uterine disorders, cardiogenic, astringent<sup>61</sup>.

## Phytochemistry

Tanaka T et al (1990) determined the structure of granatin – A, B<sup>91</sup>.

Satomi H et al (1993) reported the presence of casuarinin, gallaglydilactone, pedunculagin, tellimagrandin<sup>92</sup>.





Poyrazoglu E et al (2002) stated the presence of gallic acid<sup>73</sup>.

Noda Y et al (2002) reported the presence of delphinidine, pelargonidine, cyanidine<sup>77</sup>.

Van Elswijk D.A. et al (2004) reported the presence of luteolin, quercetin, kaempferol<sup>81</sup>.

## **Pharmacology**

Dhawan B.N et al (1958) reported that aqueous extract showed uterine stimulant activity in rats<sup>93</sup>.

Gujral M.L et al (1960) stated antifertility activity<sup>94</sup>.

Kim N.D et al (1974) stated that methanolic extract showed anthelmintic effect (12 mg/kg)<sup>95</sup>.

Mascolo N et al (1987) reported that ethanolic extract showed weak antiinflammatory activity (100 mg/kg)<sup>84</sup>.

Sato A et al (1990) stated that hot aqueous extract showed antitumor effect (120 mg/kg)<sup>96</sup>.

Pillai N.R et al (1992) reported hydroalcoholic extract showed antidiarrhoeal activity (500 mg/kg, i.g)<sup>86</sup>.

Hukkeri V.I et al (1993) stated that aqueous extract showed anthelmintic activity<sup>97</sup>.

Khenouf S et al (1999) reported antiulcer activity in rats<sup>98</sup>.

Roos R.G et al (2001) stated that powder of the plant showed immune stimulant effect (100 mg/kg, i.g) in rabbits<sup>99</sup>.

Noda Y et al (2002) stated that ethanolic extract showed antioxidant activity (IC<sub>50</sub> 10 mg/ml)<sup>77</sup>.

Murthy K.N.C et al (2002) reported that methanolic extract showed hepatoprotective activity (50 mg/kg)<sup>100</sup>.

Aslant M et al (2003) stated antidiabetic activity (500 mg/kg) in rats<sup>101</sup>.

Bafna P et al (2003) reported that methanolic extract showed antimotility, antiulcer, anti diarrhoeal activity in animals<sup>102</sup>.

Ajaykumar K.B et al (2005) stated that methanolic extract showed gastro protective effect (500 mg/kg)<sup>103</sup>.

Qnais P et al (2007) reported that aqueous extract showed antidiarrhoeal activity<sup>104</sup>.

Sestili, P et al (2007) stated cytoprotective effect<sup>105</sup>.

## **Microbiological Review**

Naovi S.A.H et al (1991, 1992) reported that aqueous and ethanolic extract showed anti bacterial activity (10 mg/ml) and antiamoebic activity (10mg/10gm)<sup>106</sup>.

Miranda D et al (1993) stated that petroleum ether extract showed antibacterial activity<sup>107</sup>.

Perez C et al (1994) reported that hot aqueous extract showed antibacterial activity<sup>89</sup>.

Goto W et al (1996) stated that aqueous extract showed antiviral activity (1mg /ml)<sup>108</sup>.

Prasanth D et al (2001), Ahmed I et al (2001) were reported equivocal effect in antibacterial activity<sup>109</sup>.

Ahmed I et al (2003) stated that acetone or methanol extract was showed anti – MRSA activity<sup>110</sup>.

## **Leaves**

### **Ethnomedical information**

Arnason T et al (1980) stated that hot aqueous extract used in women's disorder as local application<sup>111</sup>.

Ilham M et al (1995) reported that infusion used as tonic<sup>112</sup>.

Singh V.K et al (1996) stated leaf extract used in menstruation disorders<sup>66</sup>.


Nadkarni K.M et al (1954)<sup>113</sup>, Jafri M.A et al (2000)<sup>29</sup>, Ross R.G et al (2001)<sup>99</sup> were reported that paste used in conjunctivitis as local application.

Nadkarni K.M et al (1954) stated that juice used as an astringent, styptic<sup>113</sup>.


## Phytochemistry

Elgamal M.H.A et al (1965) reported the presence of **ursolic acid**, oleanolic acid, betulic acid<sup>114</sup>.

### URSOLIC ACID



### OLEANOLIC ACID



Fayez M.B.E et al (1967) reported the presence of **ursolic acid**, betulic acid,  $\beta$ -sitosterol<sup>115</sup>.

Robert M.F et al (1967) stated the presence of unstable alkaloid [2-(2-propenyl)- $\Delta'$  – Piperidine]<sup>116</sup>.

Gawienoski A.Metal (1969) reported the presence of pregnenolone<sup>117</sup>.

Pavanasasivam G et al (1974) reported the presence of betulinic acid<sup>118</sup>.

Tawfik N.I et al (1978) stated the presence of alkaloids, carotene, coumarins<sup>119</sup>.

Tanaka T et al (1985) reported the presence of corilagin, granaitin – A, B, strictinin, punicafolin<sup>120</sup>.



Kirillova V.V et al (1988) stated the presence of delphinidine<sup>35</sup>.

Nawwar M.A.M et al (1994) reported the presence of brevifolin, punicafolin, granaitin-B, xanthoxylin, ellagic acid<sup>121</sup>.


Nawwar M.A.M et al (1994) reported the NMR structure analysis of apigenin, luteolin, piperidine alkaloids<sup>122</sup>.

Anonymous (2005) mentioned reported the presence of **ursolic acid**, and betulic acid<sup>22</sup>.


Lansky E.P. et al (2007) mentioned the presence of apigenin, brevifolin carboxylic acid 10-mono phosphate sulphate, apigenin – 4'-O- $\beta$  - glucopyranoside, luteolin – 4'-O- $\beta$ -glucopyranoside, luteolin – 3'-O- $\beta$  - glucopyranoside, luteolin – 3'-O- $\beta$  - xylopyranoside, puniclain, punicalagin, corilagin, punicafolin, piperidine alkaloids (N-(2',5' – Dihydroxy phenyl pyridium chloride)<sup>74</sup>.




**PIPERIDINE ALKALOID**




**APIGENIN**



**BREVIFOLIN CARBOXYLIC ACID**



**LUTEOLIN 3- PYRANOSIDE**



## Pharmacological

Lei F.X.N et al (2007) reported antiobesity action<sup>123</sup>.

## Microbiology

Collier W.A. et al (1949) stated that the saline extract showed antibacterial activity in agar plate method<sup>124</sup>.

Misas C.A.J et al (1979) stated that aqueous, ethanol, acetone extracts showed antibacterial activity<sup>125</sup>.

Ayudhaya T.D et al (1987) stated that methanolic extract was inactive against *P.falciparum*<sup>126</sup>.

Ilham M et al (1995) reported that ether extract was inactive in tumor promotion effect in cell culture method in mouse<sup>112</sup>.

Alkofahi A et al (1997) reported that ethanolic extract of shade dried leaf and stem showed antibacterial, anti yeast activity in agar plate method<sup>127</sup>.

## Seed

John D (1984) reported that mature seeds used in hemorrhoids<sup>41</sup>.

Okamoto J.M et al (2004) stated that seed oil used as an antioxidant<sup>60</sup>.

Anonymous (2005) mentioned that seed oil used in stomachic<sup>22</sup>.

## Phytochemistry

Heftmann E et al (1966) identified the presence of esterone<sup>128</sup>.

Ahmed R et al (1995) isolated and identified the presence of **Ursolic acid**<sup>129</sup>.

Schubert S.Y et al (1999) reported puniceic acid, linoleic acid, stearic acid, palmitic acid and Oleic acid<sup>130</sup>.


Kim N.D et al (2002) reported the presence of 17 –  $\alpha$  – estradiol,  $\gamma$  – tocopherol<sup>78</sup>.

### PUNICIC ACID



Lansky EP et al (2007) mentioned that the presence  $\beta$ -Sitosterol testosterone,  $17\alpha$  estradiol, tocopherol, cereboside<sup>74</sup>.

### $\beta$ - SITOSTEROL



### Pharmacology

Dean P.D.G. et. Al (1971) stated uterine relaxation, esterogenic effect (0.2 ml, 0.4 ml)<sup>131</sup>.

Lee J.W et al (1992) reported that aqueous extract showed weak hepatoprotective effect (1mg/ml)<sup>132</sup>.

Abd El Wahab et al (1998) stated that seed oil showed esterogenic, androgenic effect (15 mg / Kg., 40 mg/kg; s.c)<sup>133</sup>.

Das A.K et al (1999) reported that methanolic extract showed antidiarrhoeal activity (200 mg/kg, i.g.)<sup>134</sup>.



Schubert S.Y et al (1999) stated that seed oil showed antioxidant, eicosanoid enzyme inhibition effect<sup>125</sup>.

Van Elswijk D.A. et al (2004) reported that seed oil showed antiproliferative effect in human breast cancer<sup>81</sup>.

Selvasubramanian S. et al (2000) stated that seed powder showed anti nematodal effect (0.75gm/kg)<sup>135</sup>.

Kwak H.M et al (2005) reported that seed husk showed  $\beta$ -secretase inhibitory activity<sup>136</sup>.

Jurenka M.T.J (2008) stated anti-inflammatory, antioxidant, prostate cancer activities<sup>38</sup>.

## **Bark**

### **Ethnomedical Information**

Singh V.P et al (1980) stated that aqueous extract used in leucorrhea, leprosy, menorrhagia<sup>137</sup>.

Jafri M.A et al (2000) reported that decoction used in dysentery<sup>29</sup>.

Bharadwaj S. et al (2003) stated the bark used for dysentery in Mizoram tribal medicine<sup>138</sup>.

Anonymous (2005) mentioned that decoction used as taenicide<sup>22</sup>.

## **Phytochemistry**

Tanaka T et al (1985)<sup>120</sup>, Neuhofer H et al (1993)<sup>139</sup> Lansky E.P et al (2007)<sup>24</sup> were reported the presence of punicalin, punicalagin, punigluconin, pelletierine, punicacortin – A, B, C, D<sup>120</sup>.

Chauhan D et al (2001) stated the presence of quercetin, pelargonidine, ellagic acid<sup>140</sup>.

Anonymous (2005) mentioned the presence of friedlin, betulic acid, pelletierine<sup>22</sup>.

## **Pharmacology**

Tripathi S.M et al (2004) reported the bark showed enzyme inhibition AChE by molluscicidal agent<sup>141</sup>.

## **Root**

### **Ethnomedical Information**

Caius J.F et al (1923) Darivas V et al (1989) stated that hot aqueous extract used anthelmintic<sup>142</sup>.


Yazicioglu A et al 1996 reported that decoction used for removal of kidney stones<sup>143</sup>.

Bharadwaj et al (2003) stated its use in dysentery<sup>133</sup>.


## Phytochemistry

Tanaka T et al (1985)<sup>120</sup>, Neuhofer H et al (1993)<sup>134</sup>, Lansky E : P et al (2007)<sup>74</sup>, Jurenka M.T.J et al (2008)<sup>38</sup> reported the presence of punicalin, punicalagin, punicacortein – A, B, C, D, pelletierine alkaloids.

### PUNICACORTEIN- A



### PELLETIERINE ALKALOIDS



## Pharmacology

Sousa P.D et al (1974) reported that aqueous, ethanolic extract showed molluscicidal activity (1000 ppm)<sup>144</sup>.

Singhal K.C et al (1984) stated that chloroform extract showed anthelmintic effect in mice<sup>145</sup>.

Desta A.B et al (1995) reported that powder showed taenicide effect<sup>146</sup>.

## **Microbiological Review**

Kurokawa M et al (1993) reported that hot aqueous extract showed antiviral activity. (0.5, 1 mg/ml) in mice<sup>147</sup>.

## **Acute toxicological studies**

Michael, A.S., et al (1956) mentioned *Artemia Salina* as a test Organism for a bioassay<sup>148</sup>.

Vanhaecke P., et al (1981) mentioned that a short – term toxicity test with *Artemia nauplii*<sup>149</sup>.

Sleet R.B., et al (1983) Improved Methods for harvesting and counting synchronous populations of *Artemia nauplii* for use in developmental toxicology<sup>150</sup>.

Sadhana Sathaye et al (2001) mentioned Brine shrimp lethality test a bench top bioassay was carried out to screen the toxic potential of herbal preparations. Number of deaths of larvae was taken as bioactivity or toxicity<sup>151</sup>.

## **Screening Methods of Ache Inhibitory Activity**

Chung Y.K et al (2001) reported that the AChE assay was performed according to the colorimetric method of Ellman et al using acetyl thiocholine iodide as a substrate<sup>17</sup>.

Sung S.H et al (2002) reported that the AChE assay was performed according to the colorimetric method of Ellman et al using neostigmine as positive control<sup>152</sup>.

Gupta R.K (2004) mentioned that AChE inhibitory activity done by Ellman method<sup>153</sup>.

Nino J. et al (2006) reported that the AChE assay was performed according to the colorimetric method of Ellman et al using eserine as positive control<sup>14</sup>.

Adersen A et al (2007) reported that the AChE and BChE inhibitory activity was detected by a TLC bioautographic assay and the concentration of the isolated compounds that inhibited the enzyme activity by 50% (IC<sub>50</sub>) was determined by a microtitre plate assay based on Ellman method, Galanthamine HBr was used as a positive control<sup>154</sup>.

Vinutha B et al (2007) reported that the AChE inhibition assay was carried out as per the method of Atta-ur-Rahman et al (2001), and TLC bioautography for AChE inhibition was performed as per Martson et al (2002), eserine was used as positive control<sup>62</sup>.

## AIM AND OBJECTIVE

### Aim

To study the pharmacognostic, phytochemical and invitro study on acetylcholinesterase inhibitory activity of leaves of *Punica granatum L.*

**Var: Ganesh.** Family **Punicaceae.**

### Objective

The objective of the study was divided into three parts.

### Part – I

#### Pharmacognostic Studies

- ❖ Identification, collection and authentication of leaves of *P. granatum*.
- ❖ Detailed pharmacognostic study includes morphological study, microscopical study and quantitative microscopy

### Part – II

#### Preliminary Phytochemical Studies

- ❖ Preliminary phytochemical analysis of the leaf powder and different extracts.
- ❖ Identification and estimation of ursolic acid by TLC and HPLC for different extracts.

### Part III

#### ♦ **Acute toxicological study**

To perform **BSLB** (Brine Shrimp Lethality Bioassay) as a preliminary assessment of the toxicity of for different extracts of

***P. granatum L.***

#### ♦ **Acetylcholinesterase Inhibitory Activity**

### Part – A

Standardization & Validation of Ellman method which includes

- ❖ Determination of Acetylcholinesterase concentration.
- ❖ Determination of substrate (ATCI) concentration.
- ❖ Determination of Ellman reagent (DTNB) concentration.
- ❖ Determination of pH maxima.
- ❖ Determination of Temperature maxima.

### Part – B

- ❖ To evaluate the effect of the extracts having **ursolic acid** for invitro acetylcholinesterase inhibitory activity.

**Note:** The following text *P. granatum* means **Punica granatum L. Var:**

**Ganesh**

# PHARMACOGNOSTIC STUDIES

## SECTION - A

### MACROSCOPICAL STUDIES OF THE LEAVES OF

***Punica granatum Linn***<sup>22,155,156,157,158,159</sup>.

***Punica granatum Linn*** is a dicotyledonous plant belonging to the family **Punicaceae**.

On the basis of the structure of the ovary and the typical fruit (the balusta), *Punica* has been classified as the solitary genus under a separate family *Punicaceae* distinct from *Lythraceae*.

#### ***Taxonomy***

Kingdom	:	Plantae
Subkingdom	:	Tracheobionta
Division	:	Magnoliophyta
Class	:	Magnoliopsida
Sub Class	:	Rosidae
Order	:	Myrtales
Family	:	Punicaceae
Genus	:	<b><i>Punica</i></b>
Species	:	<b><i>granatum</i></b>

#### ***Synonym***<sup>22</sup>

Pomegranate

#### ***Vernacular Names***<sup>22,155,156,160,161,162</sup>

English : Pomegranate



Hindi	:	Anar, Dhalim
Kannada	:	Dalimba
Malayalam	:	Matalam
Sanskrit	:	Dadimah
Tamil	:	Madulai, Madalai Uôçû[, UôRû[
Telugu	:	Danimma, Dadima
Bengali	:	Dalimb
Marathi	:	Dalimba
Gujarathi	:	Dadam
Panjabi	:	Daru
Arabic	:	Shajratur - rumman
French	:	Greanadier
German	:	Granatbaum

### ***Geographical Distribution***<sup>22,155</sup>

#### **Native**

Considered to be Iran, Afghanistan, Baluchistan wild in the warm valleys of Himalayas 900 – 1800m and cultivated throughout India.

#### **Subspecies**<sup>22</sup>

1. Chlorocarpa
2. Porphyro carpa

#### **Habit and Habitat**<sup>22</sup>

*P.granatum* is a shrub or small tree, 5 – 10m high, dicotyledonous plant belonging to the family puniceae. It is a subtropical fruit tree, growing best in semi – arid climate where cool winters and hot summer prevail. It grows under a wide range of climatic conditions and is planted upto 35°N in USA. It stands considerable frost and is injured only when the temperature goes below – 11°C. It thrives even under desert

conditions. Although it is highly drought resistant, the pomegranate bears well only under irrigation (Plate-1,4) (Fig-1).

### **Description of the plant**<sup>22,155,161</sup>

Leaves: 2-8 cm long oblong or obovate shining above, bright green beneath, opposite, glabrous, minutely pellucid – punctuate (Plate-3,6,7).

Flowers : Scarlet red or sometimes yellow, 3.7 – 5cm long mostly solitary, some times 2 – 4 together, stamens very numerous inserted on the calyx below the petals at various levels (Plate-2).

Fruits : Globose, crowned by the persistent calyx (Plate-5).

Rind : Coriaceous and woody, interior septate with membranous walls, containing numerous seeds.

Seeds : Angular with red, pink or whitish fleshy testa.

Bark : 5 – 10 cm long and 1-3 cm wide root bark consists of irregular, curved, flattish or recurved fragments. The outer surface is rough, earthy yellow with darker patches; the inner surface is smooth and yellow, with irregular, darker, brown blotches; the fracture is short. The Stem Bark is in straighter channeled pieces or in quills, the outer surface shows occasional shallow, longitudinal furrows and pale bands of cork<sup>22</sup>.

### **Varieties**<sup>22</sup>

1. Alandi or Vadki
2. Bedana
3. Dholka

4. Fabul
5. Fandahari
6. Musket Red
7. Paper shell
8. Poona
9. Spanish Ruby
10. Vellodu
11. Ganesh

### **Cultivation**

#### **Soil**

Deep loamy soil preferably calcareous soil containing lime nodules and tolerates soil alkalinity.

#### **Propagation and culture**

Pomegranate is propagated by seed, seedlings and hard wood cuttings.

#### **Manuring**

Well – rotted, old farmyard manure mixed with ashes, groundnut cake is advantageous.

## SECTION – B

### MICROSCOPICAL STUDIES OF THE LEAVES OF *Punica granatum L.*

#### MATERIALS AND METHODS

##### ***Collection of Specimens***<sup>163,164,165,166</sup>

The plant specimens were collected from Department of Horticulture Tamil Nadu Agricultural University, Madurai, Tamil Nadu during August 2008. Care was taken to select healthy plants and for normal organs. The leaves were cut and removed from the plant and fixed in FAA (Formalin- 5 ml + Acetic acid – 5 ml + 70% ethyl alcohol-90 ml). After 24 hrs of fixing, the specimens were dehydrated with graded series of tertiary-butyl alcohol. Infiltration of the specimens was carried by gradual addition of paraffin wax (melting point 58-60°C), until TBA solution attained super saturation. The specimens were cast into paraffin blocks.

##### ***Sectioning***

The paraffin embedded specimens were sectioned with the help of rotary microtome. The thickness of the sections was 10-12 µm. After dewaxing the sections were stained with toluidine blue. Since toluidine blue is a polychromatic stain, the staining results were remarkably good and some cyto chemical reactions were also obtained. The dye rendered pink color to the cellulose walls, blue to the lignified cells, dark green to suberin, violet to the mucilage, blue to the protein bodies etc., Where ever necessary, section were also stained with safranin and fast-green and potassium iodide (for starch).

For studying the stomatal morphology, venation pattern and trichome distribution, paradermal sections (sections taken parallel to the surface of leaf) as well as clearing of leaf with 5% sodium hydroxide and epidermal peeling by partial maceration employing

jeffrey's maceration were prepared. Glycerine mounted temporary preparations were made for macerated/cleared materials.

### ***Photomicrographs***

Microscopic descriptions of tissues are supplemented with micrographs where ever necessary. Photographs of different magnifications were taken with Nikon labphoto 2 microscope unit. For normal observations bright field was used. For the study of crystals, starch grains and lignified cells, polarized light was employed. Since these structures have birefringent property, under polarized light they appear bright against dark background.

## **MICROSCOPY OF LEAF**

The leaf has thick semicellular midrib and thin lamina. In cross sectional view, the lamina exhibits distinct dorsiventral symmetry.

**Midrib** (Plate-8,8A), (Fig-2,2A)

Size : 400  $\mu\text{m}$  thick in vertical plane

600  $\mu\text{m}$  wide in horizontal plane.

has wide dorsal concavity and abaxial side hemispherical.

**Epidermis** (Plate-9,9A,9B)

Small elliptical cells, adaxial in surface view, the cells are either rectangular or polygonal with slightly wavy anticlinal walls. In the cells stained with safranin thin cuticular striations are seen prominently, which are parallel to each other.

**Abaxial epidermis**

Stomata anomocytic (Ranunculaceae), no distinct subsidiary cells are seen. Walls are undulate, amoeboid outlined, with deep folds in stomata. The guard cells are oblong, elliptic and have narrow slit like aperture.

**Vascular bundle**

Simple, wide and bowl shaped with adaxial cavity.

**Xylem**

Dense parallel lines, narrow thick walled angular in outline.

**Phloem**

Thin, present in abaxial layer.

**Lamina**

80µm thick and has thick adaxial epidermis which consists of wide rectangular cells 20 µm in thick (Plate-10,10A,10B).

**Mesophyll**

Single layer adaxial palisade cells, 20-30 µm in height, spongy parenchyma about five layers of large, circular closed arranged cells.

**Idioplast**

Specially modified, dilated cavities bearing calcium oxalate crystals are frequently seen. Crystals may be prismatic (20-40 µm thick) or druses (30µm thick).

**Venation Pattern (Plate-11,11A)**

Secondary and tertiary veins are uniformly thin and wavy. Some vein islets are distinct. The vein terminations are short, straight ends or simple.

**Petiole (Plate-12,12A,12B)**

The proximal end of petiole side semi circular with wide abaxial, and concavity two short and thick lateral wings, 1.2mm in vertical axis and 1.4mm in horizontal axis.

#### **Distal end**

The distal end of petiole has deep 'V' shape adaxial groove, long and prominent wings, which is 1mm vertical, 1.25mm horizontal, epidermal layer of small squarish cells. Ground tissue is parenchymatous which are angular thick walls and compact. Vascular stand is single, arc shaped, having denser parallel files of long, narrow xylem elements which are thick walled with narrow lumen. Phloem prominent in the lower part of the xylem, vascular strand is 600µm wide, 250µm thick.

### **POWDER MICROSCOPY OF LEAF**

#### **Organoleptic characters**

Nature -	Coarse
Colour -	Green
Odour -	Agreeable Odour
Taste -	Tasteless

The powder microscopy of the leaf powder reveals the following characters (Fig-3)

- Epidermal cells with thin & slightly wavy anticlinal walls.
- Anomocytic stomata (Ranunculaceous)
- Spongy parenchyma with prismatic crystals
- Xylem, phloem vessels
- Fragments of leaf

## SECTION – C

### QUANTITATIVE MICROSCOPY FOR LEAVES OF *P. grantum* L.

#### ***Microscopic Schedules***<sup>167,168,169,170,171</sup>

The vein islet number, vein terminal number, stomatal number and stomatal index were determined on fresh leaves using standard procedures.

#### ***A. Vein islet number and Vein terminal number***

The term vein islet is used to denote the minute area of photosynthetic tissue encircled by the ultimate divisions of the conducting strands. The number of vein islets per sq. mm., area is called vein islet number.

Vein terminal number may be defined as the number of vein terminals present in one sq., mm. area of the photosynthetic tissue.

#### ***Determination of Vein Islet Number and Vein Termination Number***

Leaflets were cleared in chloral hydrate, stained and mounted on a slide.

A camera lucida is set up and by means of a stage micrometer the paper is divided into squares of 1mm<sup>2</sup> using a 16mm objective. The stage micrometer is then replaced by the cleared preparation and the veins are traced in four contiguous squares, either in a square 2mm x 2mm (or) rectangle 1mm x 4 mm.

When counting, it is convenient to number each vein-islet on the tracing. Each numbered area must be completely enclosed by veins, and those which are incomplete are excluded from the count if cut by the top and left-hand sides of the square (or) rectangle but included if cut by the other two sides.

Ten readings for vein islet and vein termination number were recorded.



**Table - 1**  
**VEIN ISLET NUMBER AND VEIN TERMINATION NUMBER OF**  
***P. granatum L.***

Observation number	Vein Islet Number	Vein Termination	Number
1	32	21	
2	29	25	
3	31	28	
4	32	22	
5	30	25	
6	27	25	
7	24	23	
8	33	25	
9	37	24	
10	36	27	
<b>Range</b>	<b>Minimum</b>	<b>Average</b>	<b>Maximum</b>
Vein islet Number	24	31	37
Vein Termination Number	21	24	28

### **Stomatal Number**

Stomatal number is defined as the number of stoma present in one square mm area of the photosynthetic tissues.

### **Method**

Using fresh leaves, replicas of leaf surface may be made which are satisfactory for the determination of stomatal number and stomatal index. An approximate 50% gelatin and water gel is liquified on a water – bath and smeared on a hot slide. The fresh leaf is added, the slide inverted and cooled under a tap and after about 15-30 min the specimen is stripped off.

The imprint on the gelatin gives a clear outline of epidermal cells, stomata and trichomes.

**Table - 2**  
**STOMATAL NUMBER**

Observation Number		Lower epidermis	
1		209	
2		213	
3		203	
4		187	
5		217	
6		196	
7		205	
8		212	
9		217	
10		194	
Range	Minimum	Average	Maximum
Lower epidermis	187	205	217

### **B. Stomatal Index**

It is the percentage, which the numbers of stomata from the total number of epidermal cells, each stoma being counted as one cell.

$$I, \text{ Stomatal index} = S/S+E \times 100$$

Where      S = Number of stomata per unit area

E= Number of epidermal cells in the same unit area

### **Determination of Stomatal Index**

The procedure adopted in the determinations of stomatal number was observed under high power (45 x).The epidermal cells and the stomata were counted. From these values the stomatal index was calculated using the above formula.

**Table – 3**  
**STOMATAL INDEX**

Observation Number		Lower epidermis	
1		12.16	
2		9.82	
3		10.80	
4		12.24	
5		10.12	
6		10.74	
7		10.71	
8		11.80	
9		9.42	
10		10.62	
Range	Minimum	Average	Maximum
Lower epidermis	9.42	10.84	12.24

**Section - C**

**QUANTITATIVE SCHEDULES FOR LEAVES OF**  
***P. granatum L.***

***Ash Value***

The ash values were determined by using air dried powder of the leaf as per the official method.

***Total ash***

Two grams of the air dried leaf powder was accurately weighed in a platinum crucible separately. The powder was scattered into a fine even layer on the bottom of the crucible and incinerated by gradually increasing the temperature not exceeding 450°C, until free from carbon. Then it was cooled and weighed for constant weight. The percentage of ash with reference to the air dried powder was calculated.

**Water soluble Ash**

The ash obtained from the total ash procedure was boiled with 25 ml of water for 5 minutes and the insoluble matter was collected on an ash less filter paper and washed with hot water. Then it was ignited for 15 minute at a temperature not exceeding 450°C. The weight of the insoluble matter was subtracted from the weight of the total ash. The difference in weight represents the water soluble ash. The percentage of water soluble ash was calculated with reference to the air dried powder.

**Acid insoluble ash**

The ash obtained from the total ash was boiled for five minutes with 25 ml of dilute hydrochloric acid. The insoluble matter was collected in a tarred sintered glass crucible. The residue was washed with hot water, dried and weighed. The percentage of acid insoluble ash with reference to the air dried drug was calculated.

**Table - 4**  
**ASH VALUES FOR THE LEAVES OF *P. granatum L.***

Observation Number	Total Ash (%)	Acid Insoluble ash (%)	Water soluble Ash (%)
1	11.45	1.46	-
2	11.26	1.52	-
3	10.90	1.50	-
4	11.12	1.53	-
5	11.49	1.56	-
6	10.80	-	2.96
7	11.20	-	2.60
8	10.91	-	2.52
9	11.12	-	3.02
10	10.78	-	2.90

Range			
Minimum	10.78	1.46	2.52
Average	11.10	1.51	2.8
Maximum	11.49	1.56	3.02

#### ***Determination of Loss on Drying***

For the determination of loss on drying, the method described by wallis was followed.

One gram of the powdered leaf was accurately weighed in a tarred Petri dish, previously dried under the conditions specified in IP '96. The powder was distributed as evenly as practicable, by gentle sidewise shaking. The dish was dried in an oven at 100 – 105° c for 1 hour. It was cooled in a desiccator and again weighed. The loss on drying was calculated with reference to the amount of the dried powder taken.

**Table - 5**

#### **PERCENTAGE LOSS ON DRYING FOR THE LEAVES OF *P. granatum*L.**

Observation Number		Loss on Drying (%) W/W	
		Leaf	
1		8.90	
2		8.50	
3		9.10	
4		8.60	
5		9.00	
Material	Minimum	Average	Maximum
Leaf	8.50	8.82	9.10

#### ***Extractive Values***

#### ***By using solvents successively with increasing order of polarity<sup>172</sup>***

Five grams of the coarsely powdered leaf was extracted continuously in soxhlet apparatus for six hours individually, separately with solvents of increasing order of

polarity. After six hours the solvents was removed and evaporated to dryness in a tarred flat bottomed shallow dish, dried at 105°C and weighed. The percentage of the individual solvent soluble extractive value was calculated with reference to the air dried powder.

**Table – 6**  
**EXTRACTIVE VALUES (SUCCESSIVE SOLVENTS)**

<b>Solvents</b>	<b>Extractive Value (%)</b>
	<b>Leaf</b>
Hexane	1.13
Chloroform	2.66
Acetone	7.66
Ethanol	11.13
Water	16.8

## PHYTOCHEMICAL STUDIES

### SECTION – A

#### PHYTOCHEMICAL STUDIES FOR THE LEAF OF *P.granatum*

The plant *P. granatum L.* was collected from Department of Horticulture Tamil Nadu Agricultural University, Madurai, in Tamilnadu during the first week of August and it was Authenticated by the Taxonomist and Horticulturist. The leaves portion was washed thoroughly and dried in shadow. The shadow dried leaves were powdered separately and then subjected to the following preliminary phytochemical studies.

#### ORGANOLEPTIC EVALUATION

Nature of the Powder	:	Coarse
Colour	:	Green
Odour	:	Distinct odour
Taste	:	Taste less
Shaken with Water	:	No Frothing occurs
Pressed in between two filter paper	:	No oily mark on the paper.

## **PHYTOCHEMICAL STUDIES FOR THE LEAF POWDER AND EXTRACTS OF *P. granatum* L.173,174,175,176**

Powdered Materials and their individual extracts obtained from different increasing polarity were subjected to the following chemical test and the results were presented in the table.

### ***Test for Alkaloids***

#### ***Various procedures to liberate alkaloids***

- ❖ Powdered drug was mixed thoroughly with 1 ml of 10% ammonia solution and then extracted for 10 minutes with 5 ml methanol, under reflux. The filtrate was then concentrated.
- ❖ Powdered drug was mixed thoroughly with 1 ml of 10% sodium carbonate solution and then extracted for 10 minutes with 5 ml methanol, under reflux. The filtrate was then concentrated.
- ❖ Powdered drug was ground in a mortar for about 1 minute with 2 ml of 10% ammonia solution and then thoroughly mixed with 7 gram basic aluminum oxide. The mixture was then loosely packed in to a glass column and 10 ml chloroform was added, eluted, dried and methanol was added.
- ❖ Powdered drug was shaken for 15 minute with 15 ml of 0.1 N sulphuric acid and then filtered. The filter was washed with 0.1 N sulphuric acid to a volume of 20 ml filtrate; 1 ml concentrated ammonia was then added. The mixture was then shaken with two portions of 10 ml diethyl ether. The ether was dried over anhydrous sodium sulphate, filtered and evaporated to dryness and the resulting residue was dissolved in methanol.
- ❖ Powdered drug was mixed with one gram of calcium hydroxide and 5 ml of water, made into a smooth paste and set aside for 5 minutes. It was then evaporated to



dryness in a porcelain dish on a water bath. 20 ml of 90% alcohol was added, mixed well and then refluxed for half an hour on a water bath. It was then filtered and the alcohol was evaporated. To that dilute sulphuric acid was added.

The above made extracts were tested with various alkaloid reagents and the results were as follows.

1. <b>Mayer's reagent</b>	- Cream color precipitate	} Indicating the <b>presence</b> of alkaloids
2. <b>Dragendorff's reagent</b>	- Reddish brown precipitate	
3. <b>Hager's reagent</b>	- Yellow precipitate	
4. <b>Wagner's reagent</b>	- Reddish brown precipitate	

#### ***Test for purine group (Murexide test)***

The residue obtained after the evaporation of chloroform was treated with 1 ml of hydrochloric acid in a porcelain dish and 0.1g of potassium chlorate was added and evaporated to dryness on water bath. Then the residue was exposed to the vapours of dilute ammonia solution.

No purple colour was obtained indicating the **absence** of purine group of alkaloids.

#### ***Test for Carbohydrates***

##### **❖ Molisch's test**

The aqueous extract of the powdered material was treated with alcoholic solution of  $\alpha$  - naphthol in the presence of sulphuric acid.

Purple colour was obtained indicating the **presence** of carbohydrates.

##### **❖ Fehling's test**

The aqueous extract of the powdered material was treated with Fehlings I and II solution and heated on boiling water bath.

Reddish brown precipitate was obtained indicating the **presence** of free reducing sugars.

❖ ***Benedict's test***

The aqueous extract of the powdered drug was treated with Benedict's reagent and heated over a water bath.

Reddish brown precipitate was obtained indicating the **presence** of reducing sugars.

***Test for Glycosides***

***General test***

❖ ***Test A***

200 mg of the powdered drug was extracted with 5 ml of dilute sulphuric acid by warming on a water bath, filtered and neutralised with 5% sodium hydroxide solution. Then 0.1 ml of Fehlings solution A and B were added, until it becomes alkaline and heated on a water bath for 2 mts.

❖ ***Test B***

200 mg of the powdered drug was extracted with 5 ml of water instead of sulphuric acid. Boiled and equal amount of water was added instead of sodium hydroxide solution. Then 0.1 ml of Fehlings solution A and B were added, until it becomes alkaline and heated on a water bath for 2 mts.

The quantity of red precipitate formed in test A is greater than in test B indicating the **presence** of glycosides.

\* ***Anthraquinones***

❖ ***Borntrager's test***

The powdered leaf was boiled with dilute sulphuric acid, filtered and to the filtrate benzene was added and shaken well. The inorganic layer was separated and ammonia solution was added slowly.

No color reaction was observed in ammoniacal layer indicating the **absence** of anthracene derived glycosides.

❖ ***Modified Borntrager's test***

About 0.1 gram of the powdered leaf was boiled for two minutes with dilute hydrochloric acid and few drops of ferric chloride solution was added, filtered while hot and cooled. The filtrate was then extracted with benzene and the benzene layer was separated. Equal volume of dilute ammonia solution was added to the benzene extract and shaken well.

No color was observed in ammoniacal layer indicating the **absence** of anthracene derived glycosides.

***Test for cyanogenetic glycosides***

Small quantity of the powdered leaf was placed in a stoppered conical flask with just sufficient water to cover it. A sodium picrate paper strip was inserted through the stopper so that it was suspended in the flask and it was set aside for 2 hours in a warm place.

No change in the colour of the sodium picrate paper was observed indicating the **absence** of cyanogenetic glycosides

✱ ***Test for cardiac glycosides***

❖ ***Keller Killiani test***

About 1 gram of the powdered leaf was boiled with 10 ml of 70% alcohol for two minutes, cooled and filtered. To the filtrate 10 ml of water and 5 drops of solution of lead sub acetate were added and filtered. The filtrate was then extracted with chloroform and

the chloroform layer was separated and evaporated to dryness. The residue was dissolved in 3 ml of glacial acetic acid containing a trace of ferric chloride. To this 3 ml of concentrated sulphuric acid was added to the sides of the test tube carefully.

No reddish brown layer acquiring bluish green color after standing was observed indicating the **absence** of deoxy sugars of cardiac glycosides.

#### ❖ *Raymond Test*

To the alcoholic extract of the leaf, hot methanolic alkali was added.

No Violet color was produced indicating the **absence** of cardiac glycosides.

#### ❖ *Legal's Test*

To the alcoholic extract of the powdered drug, pyridine and alkaline sodium nitro pruside solution were added.

No blood red color was formed indicating the **absence** of cardiac glycosides.

#### *Coumarin glycosides*

A small amount of powdered leaf was placed in test tube and covered with a filter paper moistened with dilute sodium hydroxide solution. The covered test tube was placed on water bath for several minutes. Then the paper was removed and exposed to UV light.

No green fluorescence was observed indicating the **absence** of coumarin glycosides.

#### *Test for Phytosterols*

The powdered leaf was first extracted with petroleum ether and evaporated. The residue obtained was dissolved in chloroform and tested for sterols.

#### ❖ *Salkowski Test*

Few drops of concentrated sulphuric acid were added to the above solution, shaken well and set aside.

The chloroform layer of the solution turned red in color indicating the **presence** of sterols.

#### ❖ *Libermann – Burchard's Test*

To the chloroform solution few drops of acetic anhydride was added and mixed well 1 ml of concentrated sulphuric acid was added through the sides of the test tube and set aside for a while.

A brown ring was formed at the junction of the two layers and the upper layer turned green indicating the **presence** of sterols.

#### *Test for Saponins*

About 0.5 gram of the powdered leaf was boiled gently for 2 minute with 20 ml of water and filtered while hot and allowed to cool. 5 ml of the filtrate was then diluted with water and shaken vigorously.

No frothing occurred indicating the **absence** of saponins.

#### *Test for Tannins*

To the aqueous extract of the powdered leaf, few drops of ferric chloride solution were added.

Bluish black color was produced, indicating the **presence** of tannins.

#### ❖ *Gold beater's skin test*

2% hydrochloric acid was added to a small piece of gold beater skin and rinsed with distilled water and placed in the solution to be tested for five minutes. Then washed with distilled water and transferred to a 1% ferrous sulphate solution.

Formation of brown color indicates the **presence** of tannins.

### ***Test for Proteins and Free Aminoacids***

#### **❖ *Millon's test***

The aciduous alcoholic extract of the powdered leaf was heated with Millon's reagent.

The colour was changed to red on heating indicating the **presence** of proteins.

#### **❖ *Biuret test***

To the alcoholic extract of the powdered leaf 1 ml of dilute sodium hydroxide was added. Followed by this one drop of very dilute copper sulphate solution was added.

Violet color was obtained indicating the **presence** of proteins.

#### **❖ *Ninhydrin Test***

To the extract of the powdered drug, ninhydrin solution was added, and boiled.

Formation of violet color indicating the **presence** of Aminoacids

### ***Test for Mucilage***

To the aqueous extract of the powdered leaf, ruthenium red solution was added.

No Reddish pink color was produced indicating the **absence** of Mucilages.

### ***Test for Flavonoids***

#### **❖ *Shinoda Test***

A little amount of the powdered leaf was heated with alcohol and filtered. To the alcoholic solution a few magnesium turnings and few drops of concentrated hydrochloric acid were added, and boiled for 5 minutes.

Purple color was not obtained indicating the **presence** of flavonoids.

#### ❖ *Alkaline reagent test*

To the alcoholic extract of the powdered leaf, few drop of sodium hydroxide solution was added.

Yellow color was not formed, indicating the **presence** of flavonoids

#### ❖ *Zinc Hydrochloride Test*

To the alcoholic extract, mixture of zinc dust and concentrated hydrochloric acid was added.

No formation of red color indicating the **presence** of flavonoid

#### ***Test for Terpenoids***

The powdered leaf was shaken with petroleum ether and filtered. The filtrate was evaporated and the residue was dissolved in small amount of chloroform. To the chloroform solution tin and thionyl chloride were added.

Pink color was obtained indicating the **presence** of Terpenoids.

#### **Test for Volatile Oil**

About 100 gram of fresh leaves, were taken in a volatile oil estimation apparatus (Cocking Middleton apparatus) and subjected to hydro distillation for four hours.

No Volatile oil was obtained indicating the **absence** of volatile oil.

#### **Test for Fixed Oil**

A small amount of the powdered leaf was pressed in between in the filter paper and the paper was heated in an oven at 105°C for 10 minutes.

No translucent greasy spot occurred indicating the **absence** of fixed oil.

**Table - 7**

**RESPONSE TO THE PRELIMINARY PHYTOCHEMICAL SCREENING FOR THE  
CRUDE LEAF POWDER OF *P. granatum L.***

<b>S.NO</b>	<b>TEST</b>	<b>OBSERVATION</b>
<b>I.</b>	<b>ALKALOIDS</b>	
	Mayer's reagent	+
	Dragendorff's reagent	+
	Hager's reagent	+
	Wagner's reagent	+
<b>II</b>	<b>CARBOHYDRATES</b>	
	Molisch's test	+
	Fehling's test	+
	Benedict's test	+
<b>III</b>	<b>GLYCOSIDES</b>	
	General Test	+
	Anthraquinone	-
	Cardiac	-
	Cyanogenetic	-
	Coumarin	-
<b>IV</b>	<b>PHYTOSTEROLS</b>	
	Salkowski test	+
	Lieberman Burchard's test	+
<b>V</b>	<b>SAPONINS</b>	-
<b>VI</b>	<b>TANNINS</b>	+
<b>VII</b>	<b>PROTEINS AND FREE AMINO ACIDS</b>	
	Millon's test	+
	Biurett test	+
<b>VIII</b>	<b>GUMS AND MUCILAGE</b>	-
<b>IX</b>	<b>FLAVONOIDS</b>	
	Shinoda test	+
<b>X</b>	<b>TERPENOIDS</b>	+
<b>XI</b>	<b>VOLATILE OIL</b>	-
<b>XII</b>	<b>FIXED OIL</b>	-

The above described tests were also performed on the different extracts of leaf powder of *P. granatum L.* and the results were as follows,



Table – 8

**RESPONSE TO THE PRELIMINARY PHYTOCHEMICAL SCREENING FOR THE  
DIFFERENT EXTRACTS OF LEAF OF *P. granatum L.***

Tests	Hexane extract	Chloroform extract	Acetone extract	Ethanollic extract	Aqueous extract
<b>ALKALOIDS</b>					
Mayers Reagent	-	+	-	-	-
Dragendorffs reagent	-	+	-	-	-
Hagers reagent	-	+	-	-	-
Wagners reagent	-	+	-	-	-
<b>CARBOHYDRATES</b>					
Molishch's Test	-	-	-	+	+
Fehlings Test	-	-	-	+	+
Benedicts Test	-	-	-	+	+
<b>GLYCOSIDES</b>					
General Test	-	-	-	+	+
Anthraquinone	-	-	-	-	-
Cardiac	-	-	-	-	-
Cyanogenetic	-	-	-	-	-
Coumarin	-	-	-	-	-
<b>PHYTOSTEROLS</b>					-
Salkowski Test	+	+	-	-	-
Libermann Burchard Test	+	+	-	-	-
<b>SAPONINS</b>	-	-	-	-	-
<b>TANNINS</b>	-	-	-	+	+
<b>PROTEINS &amp; FREE AMINO ACID</b>					
Millons test	-	-	-	+	+
Biuret test	-	-	-	+	+
Ninhydrin test	-	-	-	+	+
<b>GUMS &amp; MUCILAGE</b>	-	-	-	-	-
<b>FLAVONOIDS</b>					
Shinoda test	-	-	+	-	-
Alkaline Reagent test	-	-	+	-	-
Zinc hydrochloric acid test	-	+	+	-	-
<b>TERPENOIDS</b>	+	+	+	+	-
<b>FIXED OIL</b>	-	-	-	-	-

“+” Indicate Positive reaction

“-” Indicate Negative reaction

## SECTION – B

### TLC & HPLC ANALYSIS FOR VARIOUS EXTRACTS OF LEAVES OF *P.granatum L.*<sup>173,177,178</sup>

Among the various methods of separating and isolating plant constituents the “chromatographic Procedure” originated by Tswett is one of the most useful techniques of general application. All finely divided solids have the power to adsorb other substances are capable of being absorbed some much more readily than others. This phenomenon of selective adsorption is the fundamental principle of chromatography.

#### Principle

When a mixture of compound is spotted on a TLC plate the compound which readily soluble and not strongly absorbed moves up readily along with this solvent. Those which are not so soluble, and are more strongly absorbed moves up less readily to the separation of the compound.

The advancement of the TLC techniques has provided the organic chemists and biochemists a tool which combines in itself sensitivity and rapidity compared to the conventional paper chromatographic technique.

#### Preparation of Extracts

The dried leaf powder of *P. granatum L.* was extracted in a Buchi rotavapor – R - 220 extraction apparatus and the extracted solution was concentrated under reduced pressure.

The extract was dissolved in Methanol. Small quantity was taken in a capillary tube and it was spotted on TLC plate 1cm above its bottom end the start points ere equally sized as for as possible.

### Development of chromatogram

The plates were developed in a chromatographic tank by using a range of solvents from non-polar to polar as a mobile phase. The plates were allowed to develop  $\frac{3}{4}$  of the length and then removed. The solvent front was immediately marked and the plates were allowed to dry. Then the plates were examined visually or under UV (or) sprayed with different reagents.

The spots were identified and Rf values were determined.

Stationary Phase	:	TLC Aluminium sheet precoated with slicagel 60 F254. (Merck)	
Mobile phase used	:	Chloroform	: Methanol
		8	: 2
Detecting Agent	:	Methanolic Sulphuric acid	

The Rf value was calculated by the following formula.

$$R_f = \frac{\text{Distance travelled by solute front}}{\text{Distance traveled by solvent front}}$$

Table – 9

RESULTS OF TLC ANALYSIS OF VARIOUS EXTRACTS FROM THE LEAVES OF *P. granatum L.*

S. No	Type of Extract	Observation	Rf value
1.	Reference Standard (ursolic acid)	1 spot obtained ❖ pink	0.25
2.	Chloroform Extract	3 spots obtained. ❖ pink ❖ yellow and ❖ green.	0.25, 0.41, 0.53
3.	Acetone Extract	3 spots obtained. ❖ pink ❖ yellow and ❖ green.	0.25, 0.43, 0.55
4.	Ethanol Extract	3 spots obtained. ❖ pink ❖ yellow and ❖ green.	0.25, 0.47, 0.58

The  $R_f$  value (0.25) of various extracts coincides with the standard of ursolic acid.

Hence the pink colour spot may be to ursolic acid. (Plate – 13)

Further the amount of ursolic acid present in various extracts of leaves of *P.granatum* were quantified using HPLC analysis.

## **“HPLC ANALYSIS OF VARIOUS EXTRACTS OF LEAVES OF P. granatum L.”**

### **High performance liquid chromatography<sup>179</sup>**

HPLC was referred to as high pressure liquid chromatography, but nowadays the term high performance liquid chromatography is performed. Since it better describes the characteristics of the chromatography and avoids creating the impression that high pressures are an inevitable pre-requisite for high performance.

A typical HPLC unit consist of the following

- A solvent reservoir and mixing system
- A high pressure pump
- A sample inlet pump
- A column (stainless steel)
- A detector and recording unit

### **Procedure**

The appropriate solvents (mobile liquid phase) from the reservoirs are allowed to enter the mixing chamber where a homogenous mixture is obtained. A pump capable of maintaining high pressures draws the solvent from the mixing chambers and pushes it through the column.

The sample is injected through a port into the high pressure liquid carrier stream between the pump and the column. The separation takes place on the columns which vary from 50 – 100cm in length and 2.3 m.m in i.d. Typical flow rates are 1-2ml/min with pressure up to several thousand psi. The column effluent passes through a non-destructive detector where a property such as ultraviolet absorbance, refractive index (or) molecular fluorescence is monitored, amplified, and recorded as a typical detector response vs retention time chromatogram. The effluent may be either discarded,

recycled, or saved for the further studies in a fraction collector which is synchronized with the detector.

### **Practical Procedure**

There are two methods which are generally used.

First method makes use of micro syringe designed to withstand high pressure. The sample is injected through a septum in an injection port, either directly on to the column packing (or) on to a small plug of inert material immediately above the column packing. This can be done while the system is under pressure, or the pump may be turned off before injection and when the pressure has dropped to near atmospheric, the injection is made and the pump switched on again. This is termed a stop flow injection.

In the second method, the sample is introduced by use of a loop injector. This consists of a metal loop of small volume which can be filled with the sample. By means of an appropriate valve, the eluant from the pump is channeled through the loop, the outlet of which leads directly on to the column. The sample is thus flushed on to the column by the eluant, without interruption of solvent flow to the column.

Repeated application of highly impure samples such as sera, urine which have preferably been deproteinated may eventually cause the column to lose its resolving power.

To prevent this occurrence a guard column is installed between the injection and the analytical column.

### HPLC Analysis of various extracts of *P. granatum* L. leaves (Fig. 5,6)

Instrument	:	Shimadzu BM – 101
Liquid Chromatogram	:	10 ATVP Shimadzu liquid chromatography
Column Used	:	C-18 ODS Column
Column No	:	SLL / P / HPLC / 68
Detector	:	SPD – 10 AVP Shimadzu UV – Vis detector
Wave length	:	210 nm
Mobile Phase	:	ACN : Methanol
Flow rate	:	0.5ml/1min
Injection volume	:	20 µl
Standard (Ursolic acid)	:	30.40mg / 100ml
Ursolic acid Potency	:	84.84

### Results

By comparing the peaks obtained from various (chloroform, acetone, ethanol) extracts of *P.granatum* with the peak area of reference standard ursolic acid, it was found that the various extracts contain ursolic acid and the HPLC data were as follows (Fig – 4 – 8).

Table – 10

RESULTS OF HPLC ANALYSIS OF VARIOUS EXTRACTS FROM THE LEAVES OF *P.granatum*

S.NO	Parameters	Standard	Type of Extract			
		Ursolic acid (Fig-4,4A,4B)	Chloroform (Fig-5,5A)	Acetone (Fig-6,6A)	Ethanol (Fig-7,7A)	Aqueous (Fig-8,8A)
1.	Weight (in mg/100ml)	30.40	421	283.60	243.50	401.20
2.	Peak Area – 1	3576647	11744297	129228	48457	Not detected
3.	Peak Area – 2	3530697	11942826	125300	52757	
4.	Peak Area – 3	3593624	-	-	-	
5.	Average	3566989.33	11843561.50	127264	50607	
6.	Standard Deviation	32556.18	140381.20	2777.52	3040.56	
7.	Assay (%w/w)	As such	20.34	0.32	0.1503	

**Calculation :**

The percentage of ursolic acid present in the Chloroform extract.

$$\begin{aligned}
 &= \frac{\text{Test Area}}{\text{Standard Area}} \times \frac{\text{Standard dilution}}{\text{Test dilution}} \times \frac{\text{Potency}}{100} \times 100 \\
 &= \frac{11843561.50}{3566989.33} \times \frac{30.40/100}{421/100} \times \frac{84.84}{100} \times 100 = 20.34\%
 \end{aligned}$$





## ACUTE TOXICOLOGICAL STUDY USING BRINE SHRIMP LETHALITY ASSAY

The importance of medicinal plants and traditional health systems solving the health care problems of the world is gaining increasing attention. Most of the developing countries have adopted traditional medical practice as an integral part of their culture.

In order to study the toxicity of these medicinal plants we performed **Brine Shrimp Lethality Bioassay** which based on the ability to kill laboratory cultured brine shrimp (*Artemia nauplii*). The brine shrimp assay was proposed by Michael<sup>148</sup> et al latter developed by Vanhaecke et al<sup>149</sup> Sleet and Brendel et al<sup>150</sup>. The assay is a useful tool for preliminary assessment of toxicity and it has been used for the detection of fungal toxins, plant extract toxicity, heavy metals, pesticides and cytotoxicity testing of dental materials.

The method is attractive because it is very simple, inexpensive and low toxin amounts are sufficient to perform the test in the micro well scale.

### ***Production of Artemia Strain***

Artemia is a non-selective filter feeder of organic detritus, micro algae and bacteria. Artemia are naturally found in salt pans, hypersaline lakes and coastal lagoons as well as in the man made Salt pans. When the cysts are inoculated in seawater for 24 hrs, the free – swimming nauplii are hatched out.

### ***Cytotoxicity Bioassay***<sup>151</sup>

Ten nauplii were drawn through a glass capillary and placed in each vial containing 4.5 ml of brine solution. In each experiment, 0.5 ml of the extract was added to 4.5 ml of brine solution and maintained at room temperature for 24 hrs under the light and surviving larvae were counted. Experiments were conducted along with control (vehicle treated), different concentrations of the chloroform extract (100-7500 ppm) in a set of three tubes per dose.

### ***Lethality Concentration Determination***

The percentage lethality was determined by comparing the mean surviving larval of the test and control tubes.  $LC_{50}$  value was obtained from the best – fit line, plotted concentration verses percentage lethality. Podophyllotoxin was used as a positive control in the bio assay (Fig – 9).

### ***Statistical Analysis***

The percentage lethality was calculated from the mean survival larvae of extract treated tubes and control.  $LC_{50}$  values were obtained by best-fit line method.

**Table - 11**  
**EFFECT OF VARIOUS CONCENTRATIONS OF CHLOROFORM**  
**FROM LEAVES OF *P. granatum* L.**  
**ON ARTEMIA NAUPLII** **EXTRACT**

Extract	Concentration in ppm	Numbers released	Numbers dead after 24 hrs	Mortality (%)	Corrected Mortality by Abbot's formula
Chloro form extract	100	10	3	30	23.3
		10	2	20	
		10	2	20	
	200	10	2	20	23.3
		10	2	20	
		10	3	30	
	500	10	3	30	33.3
		10	4	40	
		10	3	30	
	1000	10	4	40	43.3
		10	5	50	
		10	4	40	
	2500	10	3	30	43.3
		10	5	50	
		10	5	50	
	5000	10	5	50	50.0
		10	5	50	
		10	5	50	
	6000	10	6	60	63.3
		10	7	70	
		10	6	60	
	7500	10	7	70	66.6
		10	7	70	
		10	6	60	
Control		10	-	-	-
		10	-	-	-
		10	-	-	-

# PHARMACOLOGICAL SCREENING

## Introduction

In Alzheimer's Disease (AD), the brain is characterized by selective neuronal loss, neurofibrillary tangles, and extracellular deposits of insoluble amyloid that form senile plaques. The nucleus basalis of Meynert, the diagonal band of Broca, and the medial setum of the basal forebrain provide cholinergic projection to the cerebral cortex, hippocampus and amygdala. The cholinergic system is responsible for the storage and retrieval of items in memory. Its degradation correlates well with the severity of cognitive and memory impairment. Moreover, the severity of dementia is closely correlated with both synapse and neuronal loss in the neocortex and hippocampus (Plate 16 – 18).

As the cognitive dysfunction and other features of AD are mediated by the loss of function at cholinergic synapses in the neocortex and hippocampus, agents replacing the lost cholinergic function should be useful in the management of this disease.

One strategy for ameliorating symptoms of AD is the restitution of a near normal acetylcholine concentration in the synaptic cleft to enhance cholinergic neurotransmission. Acetylcholinesterase inhibitors reduced the hydrolysis of acetylcholine to boost the endogenous level of acetylcholine in the brain and thereby to boost cholinergic neurotransmission. This resulted in the improvement of cognitive function in mild to moderate AD. Some patients, however, demonstrated a dramatic improvement in cognitive scores that was readily observable in their daily functions

Ursolic acid (UA), a pentacyclic triterpene acid, has been isolated from many kinds of medicinal plants, such as *Eriobotrya japonica*, *Rosemarinus officinalis*, *Glechoma hederaceae*. Ursolic acid has been reported to produce anti-tumor activities, including the inhibition of skin tumorigenesis and inhibition of tumor promotion. It also induced tumor cell differentiation by the regulation of the expression of differentiation-

specific genes in mouse F9 teratocarcinoma cells. In addition, ursolic acid was shown to possess an anti-angiogenic effect on the chick chorioallantoic membrane, and an anti invasive activity on HT1080 human fibrosarcoma cells. It was proved that ursolic acid from *Origanum majorana* appeared to be a potent AChE inhibitor in Alzheimer's disease<sup>17</sup>.

In our study it was found that chloroform, acetone, ethanol extracts of defatted, shade dried, powdered leaves of *P.granatum* contains ursolic acid and the percentage were determined by HPLC.

The previous report of ursolic acid as potent AChE inhibitor and its presence in the leaves of *P. granatum* which is available freely at lower cost and not used for any other purpose after fruit harvest has inspired us to carryout AChE inhibitor activity.

## **METHOD**

Ellman Esterase Assay procedure was performed. The method aims to determine the rate of hydrolysis of acetylthiocholine (ATCh) by acetylcholinesterase (AChE) in tissues taken from laboratory rat<sup>17,62,152,153,154</sup>.

## **PRINCIPLE**

This assay is a spectrophotometric method, which involves two linked reactions to produce a coloured compound. The production of the compound is monitored by measuring the absorbance of light by the reaction mixture over time. ATCh is hydrolyzed enzymatically to give acetate and thiocholine. Thiocholine reacts with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) producing the yellow coloured 5 thiobis-2-nitrobenzoic acid (TNB). TNB has absorbance maxima at a wavelength of 412 nm.

## MATERIALS AND METHODS

### 1. REQUIREMENTS

Apparatus/Instrument used	Name of the Company
Microplate Reader	: Fluostar optima, BMG
Sonicator	: Analytical lab suppliers
Vortex mixer	: Serwell instruments Ltd
pH meter	: Thermo
Analytical balance	: Sartorius
Micro pipette	: Thermo

### 2. MATERIALS

Apparatus/Instrument used	Name of the Company
Eppendorf vials	: Tarson
Pipette tips 2-200 µl	: Tarson
Pipette tips 200- 1000 µl	: Tarson
Beakers	: Borosil
96 well micro plate(white)	: Becton Dickinson
Distilled water	: Spectrum
Sptula	: -

### 3. REAGENTS

Reagent used	Name of the Company
Sodium phosphate(monobasic)	: Merck
Sodium phosphate(Dibasic)	: Merck
Acetylthiocholine iodide(ATCI)	: Sigma
Acetylcholinesterase(AChE)	: Rat brain tissue
5,5 <sup>1</sup> -dithiobis-2-nitrobenzoic acid(DTNB)	: SRL
Tacrine	: Sigma

### 4. Reagent preparation

#### ❖ Phosphate buffer (0.1 M, pH 8)

2.69 grams of Dibasic sodium phosphate, 0.146 grams of monobasic sodium phosphate was added in 100 ml of double distilled water(DD water) and pH was adjusted to pH 8 and the volume was made upto 200 ml by adding DD water.

❖ **Enzyme**

100 mg of rat brain tissue was homogenized with 5 ml of phosphate buffer ; it was then aliquoted into vials under sterile conditions and stored at -80°

❖ **Substrate (ATCI)**

Molecular weight of substrate = 289.18 g.

❖ **Ellman reagent (DTNB)**

Molecular weight of DTNB = 396.35 g.

❖ **Control (Tacrine)**

Molecular weight of Tacrine = 234.73 g.

❖ **Sample**

Stock solution = 500 mg of samples were weighed and dissolved in 1000 µl DMSO (Dimethyl sulphoxide)

**PROCEDURE**

Rat striata are homogenized in 10 volumes of 0.1 M phosphate buffer(pH 8.0). Five minutes after the addition of 400 µl of homogenate, 30 µl of test compound solution at various concentrations, and 100 µl of DTNB(10mM) to 2.45 ml of 0.1 M phosphate buffer(pH 8.0) are added and AChE activity is determined at 25° C over 1 minute in a photocell after the addition of 20 µl of acetylthiocholine iodide(ATCI) as substrate.

A substrate blank(i.e., no tissue, only substrate and buffer and DTNB) should be run with each group of assays; this measures nonenzymatic substrate hydrolysis. A tissue blank(i.e., only tissue, buffer and DTNB but no substrate) should be run for each tissue to determine the degree of binding of DTNB to sulfhydryls in the tissue sample. If this is minimal after the preincubation period, then the tissue blank will not be needed on a regular basis for that tissue.



The activity was calculated by using the formula

$$\text{Velocity (V)} = \frac{\text{Change in Absorbance} / \text{min}}{\text{molar extinction coefficient} \times 12600}$$

## STANDARDIZATION AND VALIDATION OF ELLMAN METHOD

### 1. Standardization of assay using different concentrations of Enzyme

1. Into the 96 well (white) microtitre plate, 150µl (0.1M Phosphate) buffer in enzyme blank (EB), substrate blank (SB) and 140-50µl buffer in respective activity wells.
2. 50µl enzyme was added in enzyme blank, except in substrate blank well.
3. **10-100µl of enzyme** was added in respective activity wells.
4. 50µl of DTNB was added in all wells.
5. 50µl of ATCI was added in all wells except enzyme blank.
6. Absorbance was read at the intervals of 10 minutes at 405 nm in microplate reader in **duplicate**.

Table - 12

#### STANDARDIZATION OF ENZYME CONCENTRATION

Contents (µl)	EB	SB	A	B	C	D	E	F	G	H	I	J
Buffer	150	150	140	130	120	110	100	90	80	70	60	50
Enzyme	50	-	10	20	30	40	50	60	70	80	90	100
DTNB	50	50	50	50	50	50	50	50	50	50	50	50
ATCI	-	50	50	50	50	50	50	50	50	50	50	50

**Table -13**  
**EFFECT OF DIFFERENT VOLUME OF ENZYME IN AChE ACTIVITY (Fig – 10)**

S.No.	Volume of Enzyme	Absorbance	Activity
1.	10	0.04585	3.37132
2.	20	0.077	5.66176
3.	30	0.1088	8
4.	40	0.13465	9.90074
5.	50	0.14955	10.9963
6.	60	0.15215	11.1875
7.	70	0.1554	11.4265
8.	80	0.13485	9.91544
9.	90	0.12475	9.17279
10.	100	0.12755	9.37868

## Result

The volume of enzyme at 40 $\mu$ l, 50 $\mu$ l were found to be ideal concentration at which the enzyme activity will be linear. Above the enzyme volume 50 $\mu$ l showed saturation so we performed the same experiment to confirm the suitable concentration from 40 $\mu$ l, 50 $\mu$ l.

Finally, the enzyme at 50  $\mu$ l volume was selected for the assay at which the enzyme activity will be linear.

## 2. Standardization of assay using different concentration of substrate

1. Into the 96 well microtitre plate, 150  $\mu$ l buffer in enzyme blank, substrate blank and 100  $\mu$ l buffer in respective activity wells.
2. 50 $\mu$ l enzyme was added in all wells except in substrate blank
3. 50 $\mu$ l of DTNB was added in all wells.

4. 50µl of ATCI different concentrations from 4mM – 0.125mM was added in respective activity wells (A to Q).
5. Absorbance was read at the intervals of 10 minutes at 405nm in microplate reader.

**Table -14**

**STANDARDIZATION OF SUBSTRATE CONCENTRATION**

Contents (µl)	EB	SB	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q
Buffer	150	150	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
Enzyme	50	-	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50
DTNB	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50
ATCI	-	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50

**Table - 15**  
**EFFECT OF VARIOUS CONCENTRATON OF**  
**SUBSTRATE IN AChE ACTIVITY (Fig – 11)**

S.NO.	Concentration mM [S]	Absorbance. V	Activity	1/[S]	1/V
1.	4	0.092155	6.776103	-	-
2.	3.75	0.1154	8.485294	-	-
3.	3.5	0.1073	7.889706	0.285714	9.319664
4.	3.25	0.1047	7.698529	0.307692	9.551098
5.	3	0.10395	7.643382	0.333333	9.62001
6.	2.75	0.10825	7.959559	0.363636	9.237875
7.	2.5	0.1082	7.955882	0.4	9.242144
8.	2.25	0.10575	7.775735	0.444444	9.456265
9.	2	0.10935	8.040441	0.5	9.144947
10.	1.75	0.1121	8.242647	0.571429	8.920607
11.	1.5	0.11725	8.621324	0.666667	8.528785
12.	1.25	0.1153	8.477941	0.8	8.673027
13.	1	0.1083	7.963235	1	9.23361
14.	0.75	0.11205	8.238971	1.333333	8.924587
15.	0.5	0.1056	7.764706	2	9.469697
16.	0.25	0.08975	6.599265	4	11.14206
17.	0.125	0.0434	3.191176	8	23.04147

### Determination of $K_m$ value

1. Michalis - Menten graph can be plotted by taking  $[S]$  in mM concentration on X - axis and  $V$  in mM / min on Y - axis.

Michalis - Menten equation :

$$V = \frac{V_{\max}[S]}{K_m + [S]}$$

Where,  $V$  = Initial rate of production of product

$V_{\max}$  – Maximum initial rate of production of product

$[S]$  – substrate concentration

$K_m$  – Michalis - Menten rate constant (The substrate concentration that produces half the maximum velocity)

Lineweaver Burk plot is sensitive to data error and is strongly biased in fitting data in low concentration range. The reciprocal of Michalis - Menten equation gives Lineweaver Burk plot. It was plotted by taking  $1/[S]$  on X – axis and  $1/V$  on Y – axis (Fig – 12).

$$\frac{1}{V} = \frac{K_m}{V_{\max}[S]} + \frac{1}{V_{\max}}$$

$$Y = mx + c$$

Where,  $m$  = slope ( $K_m/V_{\max}$ )

$C$  = Intercept ( $1/V_{\max}$ )

From the graph we got

$$Y = 1.6114 x + 7.977$$

$$V_{\max} = 1/c = 0.1253$$

$$K_m = V_{\max} \times m$$

$$K_m = 0.2019$$

## Result

From  $K_m$  value, the substrate at **0.5 mM** was found to be the ideal concentration at which the enzyme activity will be linear.

### 3. Standardization of assay using different concentrations of Ellman reagent (DTNB)

1. Into the 96 well microtitre plate, 150  $\mu$ l buffer in enzyme blanks, substrate blank and 100  $\mu$ l buffer in respective activity wells.
2. 50 $\mu$ l enzyme was added in all wells except in substrate blank.
3. 50  $\mu$ l of DTNB different concentrations from 5.28 mM – 0.0412 mM was added in respective activity wells (A to H).
4. 50  $\mu$ l of 0.5mM ATCI was added in all wells except enzyme blank well.
5. Absorbance was read at the intervals of 10 minutes at 405nm in microplate reader.

**Table – 16**

#### STANDARDIZATION OF ELLMAN REAGENT

CONTENTS ( $\mu$ l)	EB	SB	A	B	C	D	E	F	G	H
Buffer	150	150	100	100	100	100	100	100	100	100
Enzyme	50	-	50	50	50	50	50	50	50	50
DTNB	50	50	50	50	50	50	50	50	50	50
ATCI	-	50	50	50	50	50	50	50	50	50

**Table - 17**

**EFFECT OF DIFFERENT CONCENTRATION OF  
ELLMAN REAGENT IN AChE ACTIVITY (Fig – 13)**

<b>S.No.</b>	<b>Concentration (mM)</b>	<b>Absorbance</b>	<b>Activity</b>
1.	5.28	0.0975	0.0975
2.	2.64	0.11135	0.11135
3.	1.32	0.11335	0.11335
4.	0.66	0.11945	0.11945
5.	0.33	0.1161	0.1161
6.	0.165	0.11055	0.11055
7.	0.0825	0.10365	0.10365
8.	0.0412	0.0377	0.0377

**Results**

From this experiment the ideal concentration of DTNB was found to be **0.33 mM**.

**4. Estimation of pH Maxima**

1. Into the 96 well microtitre plate, 150 µl buffer in enzyme blank, substrate blank and 100 µl buffer of different **pH 7 – 9** was added in respective activity wells (A to E)
2. 50 µl enzyme was added in all wells except in substrate blank.
3. 50µl of 0.33mM DTNB was added in all wells.
4. 50µl of 0.5mM ATCI was added in all wells except enzyme blank.
5. Absorbance was read at the intervals of 10 minutes at 405nm in microplate reader.

Table - 18

## ESTIMATION OF pH MAXIMA

Contents ( $\mu$ l)	EB	SB	ACTIVITY				
			A	B	C	D	E
Buffer	150	150	100	100	100	100	100
Enzyme	50	-	50	50	50	50	50
DTNB	50	50	50	50	50	50	50
ATCI	-	50	50	50	50	50	50

Table - 19

## EFFECT OF pH IN AChE ACTIVITY (Fig – 14)

S.No.	pH	Activity (Units)
1.	7	9.29
2.	7.5	11.64
3.	8	12.92
4.	8.5	12.045
5.	9	10.54

**Result**

It was proved from the experiment that the buffer in pH 8, showed good enzyme activity, so we have selected **pH 8** for the assay.

**5. Estimation of Temperature Maxima**

1. Into the 96 well microtitre plate, 150  $\mu$ l buffer in enzyme blank, substrate blank and 100  $\mu$ l buffer of pH 8 was added in respective activity wells.
2. 50 $\mu$ l enzyme was added in all wells except in substrate blank.
3. 50 $\mu$ l of 0.33 mM DTNB was added in all wells.



4. 50µl of 0.5mM ATCI was added in all wells except enzyme blank.
5. Absorbance was read at the intervals of 10 minutes at 405nm in microplate reader at different temperature from **28 – 42°C**.

**Table - 20**

**ESTIMATION OF TEMPERATURE MAXIMA**

Contents (µl)	EB	SB	ACTIVITY						
			A	B	C	D	E	F	G
Buffer	150	150	100	100	100	100	100	100	100
Enzyme	50	-	50	50	50	50	50	50	50
DTNB	50	50	50	50	50	50	50	50	50
ATCI	-	50	50	50	50	50	50	50	50

**Table - 21**

**EFFECT OF TEMPERATURE IN AChE ACTIVITY (Fig – 15)**

S.No.	Temp	Activity (Units)
1.	28°C	13.365
2.	30	12.85
3.	33	13.49
4.	35	13.425
5.	37	13.51
6.	39	13.245
7.	42	13.51

**Result**

It was proved from the experiment that the temperature at 37°C showed good enzyme activity, so we selected the temperature at **37°C** for the assay.

## Section B

### SCREENING OF SAMPLES FOR AChE INHIBITORY ACTIVITY

#### 1. Estimation of AChE inhibitors Tacrine, Ursolic acid and extracts

1. Into the 96 well microtitre plate, 150µl buffer in enzyme blank, substrate blank, 100 µl buffer in activity well and 50µl buffer of **pH 8** was added in activity inhibition well.
2. **50µl enzyme** was added in all wells except in substrate blank.
3. 50µl of **0.33mM DTNB** was added in all wells.
4. 50µl of **reference standard** ursolic acid, tacrine, were added in activity inhibition well.
5. 50µl of **0.5mM ATCI** was added in all wells except enzyme blank.
6. Absorbance was read at the intervals of 10 minutes at 405nm in microplate reader at **37°C**.

**Table - 22**

#### ESTIMATION OF AChE INHIBITORY ACTIVITY FOR TACRINE AND URSOLICACID

<b>CONTENTS (µl)</b>	<b>EB</b>	<b>SB</b>	<b>Activity</b>	<b>Inhibition</b>
Buffer	150	150	100	50
Enzyme	50	-	50	50
DTNB	50	50	50	50
Inhibitor	-	-	-	50
ATCI	-	50	50	50

**Table - 23**

**EFFECT OF DIFFERENT CONCENTRATION OF URSOLIC  
ACID IN AChE INHIBITION (Fig – 16)**

<b>S.No.</b>	<b>Concentration (μM)</b>	<b>% Inhibition</b>	<b>% Inhibition</b>
1.	500	96.533330	95.338870
2.	250	86.285710	86.700770
3.	125	67.174610	71.483380
4.	62.5	45.968250	50.831200
5.	31.125	28.761910	36.636830

**Table - 24**

**EFFECT OF DIFFERENT CONCENTRATION OF TACRINE  
IN AChE INHIBITION (Fig – 17)**

<b>S.No.</b>	<b>Concentration (nM)</b>	<b>% Inhibition</b>	<b>% Inhibition</b>
1.	1600.0	89.926620	92.524590
2.	800.0	85.523680	88.983600
3.	400.0	71.914610	79.868850
4.	200.0	65.510340	65.311480
5.	100.0	48.298870	49.114750
6.	50.0	29.686460	32.721310
7.	25.0	18.212140	19.213120
8.	12.5	7.938626	7.344262

**Table - 25**  
**SIGMOIDAL DOSE – RESPONSE (VARIABLE SLOPE)**

<b>Best fit values</b>	<b>Ursolic Acid</b>	<b>Tacrine</b>
Bottom	0.0	0.0
Top	100.0	100.0
Log EC <sub>50</sub>	1.787	2.049
Hillslope	1.244	0.9806
<b>EC<sub>50</sub></b>	<b>61.19</b>	<b>111.8</b>
Std. Error		
Log EC <sub>50</sub>	0.02194	0.01580
Hill slope	0.08550	0.03376
95% Confidence Intervals		
Log EC <sub>50</sub>	1.736 to 1.837	2.015 to 2.082
Hill slope	1.046 to 1.441	0.9082 to 1.053
EC <sub>50</sub>	54.46 to 68.75	103.4 to 120.9
Goodness of Fit		
Degrees of Freedom	8	14
R <sup>2</sup>	0.9820	0.9940

## **2. SCREENING OF AChE INHIBITORY ACTIVITY FOR VARIOUS EXTRACTS OF LEAF *P. granatum***

### **Preparation of the test solution :**

Test solution for the evaluation of AChE inhibitory activity were prepared by dissolving the dried extracts in DMSO (Dimethyl Sulphoxide).

The percentage inhibition and IC<sub>50</sub> data for all the extracts were presented in table No 25.

Table - 26

**EFFECT OF DIFFERENT CONCENTRATION OF VARIOUS  
EXTRACTS IN AChE INHIBITION (Fig – 18, 19, 20)**

S.NO.	Concentration (mg/ml)	% Inhibition of Extracts			
		Chloroform	Acetone	Ethanol	Aqueous
1.	4	94	76	90	Nil
2.	2	51	48	54	Nil
3.	1	26	27	29	Nil
4.	0.5	12	11	14	Nil
5.	0.25	1.3	6.4	2	Nil

Table - 27

**SIGMOIDAL DOSE – RESPONSE**

Best fit values	Type of Extract		
	Chloroform	Acetone	Ethanol
Bottom	0.0	0.0	0.0
Top	100.0	100.0	100.0
Log EC <sub>50</sub>	0.2563	0.3329	0.2507
EC <sub>50</sub>	<b>1.804</b>	<b>2.152</b>	<b>1.781</b>
Std. Error			
Log EC <sub>50</sub>	0.1469	0.06484	0.1121
95% Confidence Intervals			
Log EC <sub>50</sub>	0.1514 to 0.6640	0.1662 to 0.4996	-0.03752 to 0.5389
EC <sub>50</sub>	0.7057 to 4.613	1.466 to 3.160	0.9172 to 3.458
Goodness of Fit			
Degrees of Freedom	4	5	5
R <sup>2</sup>	0.8307	0.9451	0.8871

The data were represented by sigmoidal dose response graph (Fig. 16 – 20).

### Result

The percentage inhibition and IC<sub>50</sub> data for tacrine, ursolic acid, and various extracts were presented in Table No 27.

**Table – 28**  
**COMPARISON OF IC<sub>50</sub> VALUE AND PERCENTAGE INHIBITION OF STANDARD AND**  
**EXTRACTS IN AChE INHIBITION**

S.NO.	Standard and Extracts	Concentration	% Inhibition	IC <sub>50</sub>
1.	Tacrine	1600 nM	93%	111.8nM
2.	Ursolic acid	500 µM	95%	61.19µM
3.	Chloroform extract	4 mg / ml	94%	1.8mM
4.	Acetone extract	4 mg/ml	76%	2.1mM
5.	Ethanol extract	4 mg/ml	90%	1.8mM

## RESULTS AND DISCUSSION

This dissertation covers the investigations on pharmacognostic, phytochemicals and invitro AChE inhibition of the various extracts of defatted, shade dried, powdered leaves of ***P.granatum***, var.: Ganesh, Family:***Punicaceae***.

**In Chapter – 1 : Introduction**, We discussed medicinal plants global view → WHO views on medicinal plants – Status of India → Contribution by Tamilnadu → Modern medicine demerits → Natural products for modern medicine → Priorities in medicinal plant research → phytonutrients – The natural drugs of the future → Degenerative diseases → Alzheimer's disease → Symptoms of AD → Characteristics of AD → Current treatment → List of medicinal plants having AChE inhibition → Ursolic acid and AChE inhibition → reason for selection of plant ***P.granatum***.

**In Chapter 2 : Review of Literature**, the various literature available were categorized under ethnomedical, pharmacognostical, phytochemical, pharmacological and biological screening of entire plant, aerial parts, flower, fruit, fruit juice, peel, rind, pericarp, leaves, bark root and acute toxicological study methods and AChE inhibitory activity screening methods were reviewed.

**In Chapter 3 : Aim and Objective** were set to obtain a potential benefit to treat Alzheimer's disease by FDA approved method of AChE inhibition by considering the following reasons.

- ❖ A new effective plant based, easily available AChE inhibitor to provide a new dimension in the therapy of Alzheimer's disease.
- ❖ Hence to provide significant contribution to the chemotherapy of this disease by natural product derived compound in future in an affordable way to reduce the incidence of Alzheimer's disease.

## **Chapter : 4 Pharmacognositc studies**

### **Section : A**

Taxonomy, synonym, vernacular name, subspecies, geographical distribution, habit & habitat, subspecies which includes morphological description of all parts, of the plant and further climate, soil condition, manuring of the cultivation varieties of ***P.granatum*** were discussed in detail to identify the plant with support of photographs, and line drawings as an establishment of authenticity (Plate – 1 to 7, Fig.: 1)

### **Morphology of the Leaf**

Size	:	2 - 8 cm
Shape	:	Oblong or Obovate
Colour	:	Green
Margin	:	Entire



Base	:	Narrowed into a very short petiole
Odour	:	Agreeable Odour
Taste	:	Tasteless

**Section - B** deals with the microscopic studies of leaves of *P.granatum* to ascertain the arrangement of tissues (Plate No - 8 - 12). The T.S. of leaf through midrib of mature, young leaf and the powder analysis showed the following features (Fig - 3).

The leaf has thick semicellular midrib and thin lamina. In cross sectional view, the lamina exhibits distinct dorsiventral symmetry.

### **Midrib**

Has wide dorsal concavity and thick hemispherical abaxial part.

### **Epidermal Cells**

Are either rectangular or polygonal with slightly wavy anticlinal walls and cells are thin cuticular striations.

### **Abaxial epidermis**

Has stomata anomocytic (Ranunculaceae), no distinct subsidiary cells are seen. Walls are undulate, amoeboid outlines and guard cells are oblong, elliptic.

### **Vascular bundle**

Simple, wide and bowl shaped with adaxial cavity.

**Xylem**

Dense parallel lines, narrow thick walled angular in out line.

**Pholem**

Thin, present in abaxial layer.

**Lamina**

80  $\mu\text{m}$  thick and has thick adaxial epidermis which consists of wide rectangular cells 20  $\mu\text{m}$  in thick.

**Mesophyll**

Single layer adaxial palisade cells, 20-30  $\mu\text{m}$  in height, spongy parenchyma about five layers of large circular closed arranged cells.

**Idioplast**

Specially modified, dilated cavities bearing calcium oxalate crystals are frequently seen. Crystals may be prismatic (20-40  $\mu\text{m}$  thick) or druses (30 $\mu\text{m}$  thick).

**Venation Pattern**

Secondary and tertiary veins are uniformly thin and wavy. Some vein islets are distinct. The vein terminations are short, straight ends or simple.

**Petiole**

The proximal end of petiole side semi circular with wide abaxial, and concavity two short and thick lateral wings, 1.2mm in vertical axis and 1.4mm in horizontal axis.

### Distal end

The distal end of petiole has deep 'V' shape adaxial groove, long and prominent wings, which is 1mm vertical, 1.25mm horizontal, epidermal layer of small squarish cells. Phloem prominent in the lower part of the xylem, vascular strand is 600µm wide, 250µm thick.

**Section - C** deals with the quantitative microscopy in terms of microscopical and physical parameters and the results were tabulated from table No. 1 to 6.

The following evaluations were carried out for leaf

S.No.	Parameters	Minimum	Average	Maximum
1.	Vein islet Number	24	31	37
2.	Vein termination number	21	24	28
3.	Stomatal Number (lower epidermis)	187	205	217
4.	Stomatal Index (lower epidermis)	9.42	10.84	12.24
5.	Total Ash (% W/W)	10.78	11.10	11.49
6.	Acid insoluble ash (% W/W)	1.46	1.51	1.56
7.	Water soluble ash (% W/W)	2.52	2.8	3.02
8.	Percentage of Loss on Drying	8.50	8.82	9.10

## EXTRACTIVE VALUES (SUCCESSIVE SOLVENTS EXTRACTION)


S.NO.	Solvents	Successive Solvents Extractive Value (%)
1.	Hexane	1.13
2.	Chloroform	2.66
3.	Acetone	7.66
4.	Ethanol	11.13
5.	Water	16.8

### Chapter – 5 – Preliminary Phytochemical Studies

**Section – A** deals with the preliminary qualitative phytochemical examination of the powdered leaves of *P.granatum* and results were tabulated from Table No. : 7.

Part	Constituents Present	Constituents Absent
Leaf Powder	Alkaloids, carbohydrates, proteins, phytosterol tannins, flavonoids, terpenoids, glycosides.	Volatile Oil, Fixed oil, mucilage

The preliminary qualitative phytochemical examination of the extract obtained by individual extraction of powdered drug using various solvents of increasing polarity were carried out and the results were tabulated from Table No. 8.



Schematic representation of various constituents present in the various extracts of leaves *P. granatum* L.

**Section – B** deals with the preparation of the Chloroform, acetone, ethanol, and aqueous extracts to determine the percentage of ursolic acid present and to screen them for AChE inhibitory activity depending upon the presence of ursolic acid.

The presence of ursolic acid in the chloroform, acetone, ethanol and aqueous extracts were identified by Co-TLC and the  $R_f$  value of ursolic acid was found to be 0.25 (Table – 9, Plate - 13).

The estimation of ursolic acid content in the chloroform, acetone, ethanol and aqueous extracts were done by using HPLC analysis (Table – 10, Fig – 4 - 8)

S.No.	Type of Extract	Description	Percentage of Ursolic Acid (% w/w)
1.	Chloroform	Black Powder	20.34
2.	Acetone	Dark Brown paste	0.32
3.	Ethanol	Greenish Brown paste	0.15
4.	Water	Brown Lumps	Nil

**In Chapter - 6** The Acute toxicological study was carried out for the chloroform extract of *P.grantum* by Brine Shrimp Lethality Bioassay (Plate – 14,15).

This method is attractive because it is very simple, inexpensive and low concentration is sufficient to perform the test in micro well scale.

The methodology for cytotoxicity bioassay was discussed in this chapter. The percentage lethality was determined by comparing the mean surviving larvae of the test and control tubes.

The mortality of larvae was calculated after 24 hrs, by using Abbot's formula, it was corrected and tabulated in Table 11. The percentage of mortality recorded in the chloroform extract were 23.3, 23.3, 33.3, 43.3, 43.3, 50, 63.3, 66.6 at 100, 250, 500, 1000, 2500, 5000, 6000 and 7500 ppm respectively (Fig – 9).

The  $LC_{50}$  values were obtained from the regression plot by plotting concentration verses % lethality. Podophyllotoxin was used as a positive control – 100% mortality at 3 ppm.

**The  $LC_{50}$  values suggested that chloroform extract is non toxic, The  $LC_{50}$  values for chloroform extract by BSLB was 2100 ppm and it need further evaluation in animal model by acute and chronic toxicological study.**

## **Chapter – 7**

**Section : A** deals with description about the Alzheimer's disease, its manifestation, current therapy and its limitations, need for the research were dealt in the introduction (Plate – 16, 17, 18).

- The AChE assay was performed according to the colorimetric method of Ellman et al using ATCI as a substrate<sup>153</sup>.
- Standardization & Validation of AChE inhibitory activity.

- Initially a test trial was conducted to standardize various parameters like pH, temperature and the suitable concentrations for AChE enzyme, substrate, reagent (DTNB). The results were tabulated in Table 12 - 20 and represented graphically. From the result it was clear that the pH maxima = 8, and temperature maxima = 37°C. The optimum concentrations of AChE enzyme, substrate and reagent were found to be 50µl, 0.5mM and 0.33 mM respectively (Fig 10– 15).

**Section : B** deals with the Screening of AChE inhibitory activity of various extracts of leaves of *P.granatum*:

From the results of HPLC the percentage of ursolic acid in the various extracts prepared successively using defatted, shade dried, powdered leaves of ***p.granatum*** for chloroform, acetone, ethanol, were 20.34, 0.32, 0.15 respectively. Since all these extracts containing ursolic acid, we planned to carry out AChE inhibitory activity of these extracts along with aqueous, prepared from the above marc, since it is economic, if it is effective.

Chloroform, acetone, ethanol, aqueous extracts obtained from defatted, shade dried, powdered leaves of ***P.granatum*** by successive extraction were screened by using 0.25, 0.5, 1, 2, 4 mg/ml

The percentage inhibition for reference standard and various extracts were presented in (Table No- 22,23,25).



**EFFECT OF DIFFERENT CONCENTRATION OF URSOLIC  
ACID IN AChE INHIBITION**

<b>S.No.</b>	<b>Concentration (<math>\mu</math>M)</b>	<b>% Inhibition</b>	<b>% Inhibition</b>
1.	500	96.533330	95.338870
2.	250	86.285710	86.700770
3.	125	67.174610	71.483380
4.	62.5	45.968250	50.831200
5.	31.125	28.761910	36.636830

**EFFECT OF DIFFERENT CONCENTRATION OF TACRINE  
IN AChE INHIBITION**

<b>S.No.</b>	<b>Concentration (nM)</b>	<b>% Inhibition</b>	<b>% Inhibition</b>
1.	1600.0	89.926620	92.524590
2.	800.0	85.523680	88.983600
3.	400.0	71.914610	79.868850
4.	200.0	65.510340	65.311480
5.	100.0	48.298870	49.114750
6.	50.0	29.686460	32.721310
7.	25.0	18.212140	19.213120
8.	12.5	7.938626	7.344262

### EFFECT OF DIFFERENT CONCENTRATION OF VARIOUS EXTRACTS IN AChE INHIBITION

S.NO.	Concentration (mg/ml)	% Inhibition of Extracts			
		Chloroform	Acetone	Ethanol	Aqueous
1.	4	94	76	90	Nil
2.	2	51	48	54	Nil
3.	1	26	27	29	Nil
4.	0.5	12	11	14	Nil
5.	0.25	1.3	6.4	2	Nil

The data were represented by sigmoidal dose response graph.  
(Figure 16 - 20).

### COMPARISON OF IC<sub>50</sub> VALUE AND PERCENTAGE INHIBITION OF STANDARD AND EXTRACTS IN AChE INHIBITION

S.No.	Standard and Extracts	Concentration	% Inhibition	IC <sub>50</sub>
1.	Tacrine	1600 Nm	93%	111.8nM
2.	Ursolic acid	500 µM	95%	61.19µM
3.	Chloroform extract	4 mg / ml	94%	1.8mM
4.	Acetone extract	4 mg/ml	76%	2.1mM
5.	Ethanol extract	4 mg/ml	90%	1.8mM

From the study the percentage inhibition and IC<sub>50</sub> value for chloroform & ethanol extracts were found there 94, 1.8 mM and 90, 1.8mM respectively. **The % inhibition and IC<sub>50</sub> value for chloroform, ethanol extracts were promising at 4 mg/ml concentration level in a dose dependent manner.**

The result shows that the Chloroform and ethanol extracts were active at 4mg/ml concentration but less comparable to the standard drugs tacrine and the triterpenoid ursolic acid which are active at 1600 nM and 500 $\mu$ M concentration respectively.

It was also observed that acetone extract was comparable with that of chloroform, ethanol extract in the same concentration level in dose dependent manner (76% inhibition, IC<sub>50</sub> 2.1mM).

But aqueous extract did not inhibit the AChE enzyme activity in the same concentration level. All other extracts showed greater than 75% inhibition at 4 mg/ml concentration. In the light of the present results we can expect the leaves of *P.grantum* to be helpful in neurodegenerative disorders like AD by reducing the enzymatic degradation of acetylcholine which is only currently approved treatment of AD by USFDA and EMEA.

The component responsible for AChE inhibition activity in the chloroform extract may be due to the higher concentration of ursolic acid (20.34%). Since it was already reported that ursolic acid act as AChE inhibitor in a dose dependent and competitive / non-competitive manner with a K<sub>i</sub> value of 6 pM representing the affinity of the enzyme and inhibitor.

The alcohol, acetone activity in these investigation may act on different mechanism though it contain low concentration of ursolic acid 0.32%, 0.15% respectively.

## CONCLUSION

This dissertation covers the pharmacognostic parameters of the leaves of ***Punica granatum*, Var. Ganesh** belonging to the family: ***Punicaceae***, such as macroscopical, microscopical including powder analysis and physical standards like ash values, extractive values, etc have been studied and presented.

- ❖ Microscopical studies reveals the presence of calcium oxalate prismatic crystals, druses in the mesophyll region and uniform parallel striations in the upper epidermis along with usual leaf tissues.
- ❖ The preliminary phytochemical studies reveals the presence of alkaloid, carbohydrate, glycoside, phytosterol, tannins, proteins, flavonoids, terpenoids in leaf powder.
- ❖ TLC of the chloroform, acetone and ethanol extracts of leaves of *P.granatum* shows the presence of ursolic acid.
- ❖ The percentage of ursolic acid in chloroform, acetone, ethanol extracts were determined by **HPLC** as 20.34, 0.32, 0.15 respectively.
- ❖ The commercial exploitation of ursolic acid is recommended.

**Acute toxicological study** In the present study it was confirmed that the chloroform extract was nontoxic and the LC<sub>50</sub> value was 2100 ppm and it need further evaluation in animal model by acute & chronic toxicological studies.

### **Preliminary invitro AChE inhibitory activity**

The Ellman method for the Acetyl cholinesterase assay was standardized and validated.

The preliminary observation of the various extracts of leaves of *P.granatum* by invitro study showed significant AChE inhibitory activity in the following order in a dose dependent manner .

Chloroform extract > ethanol extract > acetone extract.

The IC<sub>50</sub> value for chloroform acetone, ethanol extracts were 1.8, 2.1, 1.8mM respectively. It is comparable with the standard drug tacrine.

It is concluded that it can be optimistic that the present investigation present a herbal drug of a safe and potential chemotherapeutic target in the treatment of Alzheimer's disease and commercial exploitation of ursolic acid extraction. AChE inhibitors, which enhance cholinergic transmission by reducing the enzymatic degradation of acetylcholine, are the only source of compound currently approved for the treatment of Alzheimer's Disease (AD) by U.S. Food and Drug Administration (USFDA) and European medicines Agency (EMA).

## REFERENCES

1. Anonymous, **“Express Pharma Pulse”**, 1996, 21, Feb. 21.
2. Handa S.S., Kapoor V.K., **“Text book of Pharmacognosy”**, 1<sup>st</sup> edn; Delhi; Vallabh Prakashan; 6, 2001, 130.
3. William Charles Evans **“Pharmacognosy”**, 15<sup>th</sup> edn; Saunders, 2005, 3.
4. Khan AJ, Khanum A, **“Role of Biotechnology medicinal and aromatic plants”**, Hussain S.J, Imam S, Gupta V.G, “Folk uses of some common plants in different parts of the world”. Ukaaz Publication, Hyderabad 2000, 30.
5. Sharma R.K., Arora R, Ed, **“Herbal drugs – A Twenty First Century Perspective”** 1<sup>st</sup> edn, New Delhi, Jaypee Brothers Medical Publishers (P) Ltd, 2006, 218.
6. Chaudri R.D, **“A practical approaches to industrial Pharmacognosy”**, “Easter Publishers, New Delhi, 1996.
7. [www.tnhealth.org/siddhamedicine](http://www.tnhealth.org/siddhamedicine)
8. Handa, **“Emerging Frontier in the areas of Hepatoprotective, Antiulcer and Adaptogenic herbal drugs”**, A national seminar organized by Indian society of Pharmacognosy; Ooty, 1993; 1-5.
9. Mukerjee K.P, **“Quality control of Herbal drugs”, - An approach to evaluation of Botanicals”**, 1<sup>st</sup> edn, New Delhi, Business Horizons Pharmaceutical Publishers, 2002, 2.
10. Harbone J.B, **“Phytochemical methods”** – A guide to modern techniques of plant analysis 3<sup>rd</sup> edn; UK. Eswar books, 1998, 36.

11. Gibbs T. Phytonutrients – **“The natural drugs of the future”**,  
[http //www.worldscibook.com/lifesci/etextbook/6358/6358-chap01.pdf](http://www.worldscibook.com/lifesci/etextbook/6358/6358-chap01.pdf).
12. <http://www.health.state.ny.us/diseases/chronic/>.
13. <http://www.en.wikipedia.org/alzheimers>.
14. Kumar V. **“Potential medicinal plants for CNS disorders: an overview”** *Phytother Res* 20 (12) 2006, 1023 – 1035.
15. Nino J, Hernandez J.A, Correa Y.M, Mosquera O.M. **“Invitro inhibition of acetylcholinesterase by crude plant extracts from Columbian flora”** *Mem Inst Oswaldo Cruz*, Rio de Janeiro 101(7), 2006, 783-785.
16. Kim S.R, Hwang S.Y, Jang Y.P, Park M, Markelonis G.J, Oh T.H, Kim Y.C, **“Protopine from *corydalis ternata* has acetylcholinesterase and anti amnesic activities”** *Planta Med.* 65(3) 1999, 218-221.
17. Chung Y.K., Heo H. J, Kim E.K, Kim H.K, Huh T.L, Lim Y, Kim S.K, Shin D.H, **“Inhibitory effect of ursolic acid purified from *Organum majorana L.* on the acetylcholinesterase”** *Molecules and cells* 11, 2001, 137-143.
18. Kennedy D.O, Scholey AB **“The Psychopharmacology of European herbs with cognition –enhancing properties”**, *Curr Pharm Des* 12(35) 2006, 4613-4623.
19. <http://www.mdidea.com/products/herbextract/ursolicacid>
20. Siang S.T, **“Use of the combined Traditional Chinese and western Medicine in the management of burns”**, *Panminerva med*, 25 (3) 1973, 197 – 202.



21. Jain S.P, Puri H.S, **“Ethnomedicinal plants of Jaunsar – Bawar Hills, Uttarpradesh, India”**, *J Ethnopharmacol*, 12 (2) 1984, 213 – 222.
22. Anonymous, **“The wealth of India”** Vol-VIII, Ph-Re, New Delhi, CSIR Publication, 2005, 317-324.
23. Shastri V.M, Tamboli S.A, Kasture V.S, Kasture S.B, Pal S.C, **“Estimation of minerals in flowers of *sesbania grandiflora* and *P. granatum*”**. *Indian journal of Natural products*, 12 (1), 1996, 13 – 15.
24. Prakash A.O, Shukla S, Mathur S, Saxena V, Mathur R, **“Evaluation of some indigenous plants for Anti-implantation activity in rats”**, *Probe* 25 (2), 1986, 151 – 155.
25. Anesini C, Perez C, **“Screening of plants used in Argentine folk medicine for Antimicrobial activity”**, *J Ethnopharmacol*, 39 (2), 1993, 119 – 128.
26. Dhawan B.N, Patnaik G.K, Rastogi R.P, Singh K.K, Tandon J.S, **“Screening of Indian plants for biological activity IV”**, *Indian J Exp Biol*, 15, 1977, 208 – 219.
27. Ayehchi Y, Soramaghi S.M.H, Shirudi M, Sourì E, **“Screening of Iranian plants for Anti microbial activity”**, *Acta Pharm Suecica*, 19 (4), 1982, 303 – 308.
28. Bellakhadar J, Claisse R, Fleurentin J, Younos C, **“Repertory of standard Herbal drugs in the Moroccan Pharmacopoeia”**, *J Ethnopharmacol*, 35 (2), 1991, 123 – 143.
29. Jafri M.A, Aslam M, Javed K, Singh S, **“Effect of *P. granatum* Linn. (flowers) on blood glucose level in normal and alloxan – induced diabetic rats”**, *J Ethnopharmacol*, 70, 2000, 309 – 314.

30. Li Y, Wen S, Kota B.P, Peny G, Qian Li G, Yamahara J, Basil D, Galis R, **“P. granatum flower extract, a potent  $\alpha$ - glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats”**, *J Ethnopharmacol*, 99, 2005, 239 – 244.
31. Wang R, Wang W, Wang L, Liu R, Ding Y, Du L, **“Constituents of the flower of *P. granatum*”**, *Fitoterapia*, 77, 2006, 534 – 537.
32. Bagri P, Ali M, Aeri V, Bhowmik M, Sultana S, **“Antidiabetic effect of *P. granatum* flowers : Effect on hyperlipidemia pancreatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes”**, *Food and Chemical Toxicology* 2008.
33. Celik I, Temur A, Isik I, **“Hepato Protective role and antioxidant capacity of Pomegranate (*P. granatum*) flowers infusion against Trichloro acetic acid – exposed in rats”**, *Foods and Chemical Toxicology*, 2008.
34. Batta A.K, Rangaswami S, **“Crystalline chemical components of some vegetable drugs”**, *Phytochemistry*, 12, 1973, 214.
35. Kirillova V.V, Kondzhariya Z.T, **“Nature of the Tannins of some subtropical plants”**, *Chem nat comp*, 23 (4), 1988, 507 – 508.
36. Huang T.H, Hpeng G, Kota B.P, Li G.Q, Yamahara J, Roufogalis B.D, Li Y, **“Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model; role of lowering circulating lipids”**, *British Journal of Pharmacology*, 145, 2005 (a), 767 – 774.
37. Huang T.H, Hpeng G, Kota B.P, Li G.Q, Yamahara J, Roufogalis B.D, Li Y, **“Antidiabetic action of *P. granatum* flower extract : activation of PPAR – gamma and identification of an active component”**, *Toxicology and Applied Pharmacology*, 207, 2005(b), 160 – 169.

38. Jurenka M.T.J, **“Therapeutic Application of Pomegranate : A Review”** *Alternative Medicine Review*, 13 (2), 2008, 128 – 144.
39. Naqvi S.A.H, Siddigi T.O, Hamdard M.E, Hameed A, **“Anti amoebic activity of rind and flowers of P. granatum Linn”**, *Journal of Sciences Islamic Republic of Iran*, 4 (1), 1992, 1- 3.
40. Kaur G, Jabbar Z, Athar M.M, Alam S, **“P. granatum (Pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice”**, *Food and chemical toxicology*, 44, 2006, 984 – 993.
41. John D, **“One hundred useful raw drugs of the Kani Tribes of Trivandrum forest division, Kerala, India”**, *Int J Crude drug Res*, 22 (1), 1984, 17 – 39.
42. Goh S.H, Soepadmo E, Chang P, Barnerjee U, Chan K.C, Deverre J.R, Hadi H, Loke S.E, Nasrulhawq A, Oo S.L, Taylor C.E, Wong W.H, Zakaria M, **“Studies on Malaysian medicinal plants : Preliminary Results”**, *Proc-fifth asian symposium on medicinal plants and spices*, 5, 1984, 473 – 483.
43. Arseculeratne S.N, gunatilaka A.A.L, Panabokke R.G, **“Studies on medicinal plants of Srilanka, park 14 : Toxicity of some Traditional medicinal herbs”**, *J Ethnopharmacol* 13 (3), 1985, 323 – 335.
44. Singh Y.N, **“Traditional medicine in Fiji; Some Herbal Folk Cures used by Fiji Indians”**, *J. Ethanopharmacol* 15 (1), 1986, 57 – 88.
45. Caceres A, Giron L.M, Alvarado S.R, Torres M.F, **“Screening of Anti-microbial activity of plants popularly used in Guatemala for the treatment of dermatomucosal diseases”**, *J Ethanopharmacol*, 20 (3), 1987, 223 – 237.

46. Nagaraju N, Rao K.N, **“A Survey of plant crude drugs of Rayalaseema, Andrapradesh, India”**, *J Ethnopharmacol*, 29 (2), 1990, 137 – 158.
47. “Anonymous”, **World health organization, “The use of Traditional medicine in primary health care”**, A manual for health workers in South – East asia, Delhi, A.I.T.B.S. Publishers and distributors, SEARO Regional health papers No : 19, 72 – 73.
48. Ghazanfar S.A, Al – Sabahi M.A, **“Medicinal plants of Northern and central Oman (Arabia)”**, *Econ bot* 47 (1), 1993, 89 – 98.
49. Desta B, **“Ethiopian Traditional herbal drugs, part III : Anti – fertility activity of 70 medicinal plants”**, *J Ethnopharmacol*, 44 (3), 1994, 199 – 209.
50. Fujita T, Sezik E, Tabata M, Yesilada E, Honda G, Takeda Y, Taanka T, Takaishi Y, **“Traditional medicine in Turkey VII. Folk medicine in middle and west black sea region”**, *Econ bot*, 49 (4), 1995, 406 – 422.
51. Navarro V, Villarreal M.L, Rojas G, Lozoya X, **“Antimicrobial evaluation of some plants used in Mexican traditional medicine for the treatment of infectious disease”**, *J Ethnopharmacol*, 53 (3), 1996, 143 – 147.
52. Vazquez F.M, Sauarez M.A, Perez A, **“Medicinal plants used in the Barros area, Badajoz province (Spain)”**, *J Ethnopharmacol*, 44 (2), 1997, 81 – 85.
53. Lamar A.Z, Fonseca G, Fuentes J.L, Cozzi R, Cundari E, Fiore M, Ricordy R, Perticone P, Degrassi F, Salvia R.D, **“Assessment of the genotoxic risk of *P. granatum* L. (Punicaceae) whole fruit extracts”**, *J Ethnopharmacol*, 115, 2008, 416 – 422.

54. Prakash A.O, Mathur R, **“Screening of Indian medicinal plants for Anti-fertility activity”**, *Indian J Exp Biol*, 14, 1976, 623 – 626.
55. Kamboj V.P, **“A review of Indian medicinal plants with interceptive activity”**, *Indian J Med Res*, 4, 1988, 336 – 355.
56. Igea J.M, Curesta J, Cuevas M, Elias L.M, Marcos C, Lazaro M, Comparied J.A, **“Adverse reaction to Pomegranate ingestion”**, *Allergy*, 46 (6), 1991, 472 – 474.
57. Alkofahi A, Atta A.H, **“Pharmacological screening of the Anti-ulcerogenic effects of some Jordanian medicinal plants in Rats”**, *J Ethnopharmacol*, 67 (3), 1999, 341 – 345.
58. Jung S.H, Lim S.S, Lee S.Y, Lee Y.S, Shin K.H, Kim Y.S, **“Aldose reductase inhibitory activity of methanol extracts from the Korean plants”**, *Nat Prod Sci*, 9 (1), 2003, 34 – 37.
59. Vidal A, Fallarero A, Pena B.R, Medina M.E, Gra B, Rivera F, Gutierrez Y, Vuorela P.M, **“Studies on the toxicity of *P. granatum* L. (Punicaceae) whole fruit extracts”**, 2003.
60. Okamoto M.J, Hamamoto Y.O, Yamato H, Yoshimura H, **“Pomegranate extract improves a depressive state and Bone properties in Menopausal syndrome model ovariectomized mice”**, *J Ethnopharmacol*, 92 (1), 2004, 93 – 101.
61. Sudeesh S, Vijaya Lakshmi N.R, **“Flavonoids from *P. granatum* – Potential antiperoxidative agents”**, *Fitoterapia*, 76, 2005, 181 – 186.
62. Vinutha B, Prasanth D, Salma K Sreeja S.L, Pratiti D, Padmaja R, Radhika S, Amit A, Venkateshwarlu K, Deepak M, **“Screening of selected Indian medicinal plants for acetylcholinesterase inhibitory activity”**, *J. Ethnopharmacol*, 109, 2007, 359 – 3.

63. Patel C, Dadhaniya P, Hingorani L, Soni M.G, **“Safety assessment of Pomegranate fruit extract : Acute and sub chronic toxicity studies”**, *Food and Chemical Toxicology*, 46, 2008, 2728 – 2735.
64. Konowalchuk J, Speirs J.I, **“Antiviral activity of fruit extracts”**, *J Food Sci*, 41, 1976, 1013.
65. Menezes S, Cordeiro L, Viana S.B, **“*P. granatum* (Pomegranate) extract is active against Dental Plaque”**, *J Herbal Pharmacotherapy*, 6, 2006, 79 – 91.
66. Singh V.K, Ali, Z.A, **“Folk medicines in primary health care : Common plants used for the treatment of fevers in India”**, *Fitoterapia*, 65 (1), 1994, 68 – 74.
67. Khan M.A, Ahmad M.A, Khan M.N, **“Antianaemic herbal drugs with special reference to Rumman juice (*P. granatum*) and Maveez munaqqa (*Vitis Vinifera*) in classical Unani Literature”**, *Hamdard Med*, 49 (3), 2006, 14 – 17.
68. Mavlyanov J.M, Islambekov S.Y, Karimdzhanov A.K, Ismailov A.I, **“Poly phenols of the fruits of some varieties of Pomegranate growing in Uzbekistan”**, *Chem, Nat Comp*, 33 (1), 1997, 98 – 99.
69. Artik N, **“Determination of Phenolic compounds in Pomegranate juice by using HPLC”**, *Fruit processing*, 8, 1998, 492 – 499.
70. Hernandez F, Melgarejo P, Barberan F.A.T, Artes F, **“Evolution of juice anthocyanins during ripening of new selected pomegranate (*P. granatum*) clones”**, *European Food Research and Technology*, 210, 10999, 39-42.

71. Gil M.I, Barberan F.A.T, Pierce H.H., Holcroft D.M, Kader A.A, **“Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing”**, *J Agr Food Chem*, 48 (10) 2000, 4581-4589.
72. Teresa S.D.P, Buelga C.S, Gonzalo J.C.R, **“Quantitative analysis of flavan 3-ols in Spanish food stuffs and beverages”**, *J of Agriculture and Food chem.*, 48, 2000, 5331-5337.
73. Poyrazoglku E, Goekmen V, Artik N, **“Organic acids and phenolic compounds in Pomegranate (*P. granatum L.*) grown in Turkey”**, *J Food compos Anal*, 15 (5), 2002, 567-575.
74. Lansky E.P, Newman R.A, **“*Punica granatum* (Pomegranate) and its potential for prevention and treatment of inflammation and cancer”**, *J Ethnopharmacol* 109, 2007, 177-206.
75. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B, **“ Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation”**, *Amer J Clin Nutr*, 71(5), 2000, 1062-1076.
76. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M, **“Pomegranate juice supplementation to Atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development Artherosclerosis”**, *J Nutr*, 131 (8), 2001, 2082-2089.
77. Noda y, Kaneynki T, Mori A, Packer L, **“Antioxidant activities of Pomegranate fruit extract and its Anthocyanidins: Delphinidin, Cyanidin and Pelargonidin”**, *J Agr Food Chem*, 50(1), 2002, 166-171.

78. Kim N.D, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R,m Ranmachandraam C, Rabi T, Kaplan B, Lansky E, **“Chemo preventive and adjuvant therapeutic potential of Pomegranate (*P. granatum*) for human breast cancer”**, *J Ethnopharmacol*, 71, 2002, 203-217.
79. Toi M, Bando H, Ramachandran c, Melnick S.J. Imai A, fife R.S, Carr R.E, Oikawa, T, Lansky E.P, **“Preliminary studies on the anti-angiogenic potential of Pomegranate fractions in vitro and invivo”**, *J Ethnopharmacol*, 6, 2003, 121-128.
80. Kawaii S, Lansky E.P, **“ Differentiation-promoting activity of Pomegranate (*P. granatum*) fruit extracts in HL-60 Human promyelocytic Leukemia cells”**, *J Med Food*, 7(1), 2004, 13-18.
81. Van Elswijk D.A, Schobel U.P, Lansky E.P. Irth H, Greef J.V.D, **“Rapid dereplication of estrogenic compounds in Pomegranate (*P.granatum*)using on-line biochemical detection coupled to mass spectrometry”**, *Phytochemistry*, 64, 2004, 233-241.
82. Heber D, Seeram N.P, Wyatt H, Henning S.M, Zhany Y.J, Ogden L.G, **“Safety and Antioxidant activity of a Pomegranate-Ellagitannin-Enriched polyphenol dietary supplement in over weight individuals with increased waist size”**, *J Agr Food Chem*, 55(24), 2007, 10050-10054.
83. Latorre D.L, Latorre F.A, **“Plants used by the Mexican kickapoo Indians”**, *Econ Bot*, 31, 340-357.
84. Mascolo N. Autore g., Capasso F, Menghini A, Fasul M.P, **“Biological screening of Italian medicinal plants for Anti-inflammatory activity”**, *Phytother Res*, (1), 1987-28-31.



85. Heinrich M, Rimpler H, Barren N.A, **“Indigeneous phytotherapy of Gastro-intestinal disorders in a lowland mixe community (Oaxaca, Mexico), *J Ethnopharmacol*, 36(1), 1992-63-80.**
86. Pillai N.R, **“Antidiarrhoeal activity of *P. granatum* in experimental animals”, *Int J Pharmacog*, 30(3), 1992, 201-204.**
87. Defeo V, Sanatore F, **“Medicinal plants and phytotherapy in the Amalfitan coast, Salerno province, Camapania, Southern Italy”, *J Ethnopharmacol*, 39(1), 1993, 39-51.**
88. Bhattarai N.K, **“Folk herbal remedies for diarrhoea and dysentery in central Nepal”, *Fitoterapia*, 64(3), 1993, 243-250.**
89. Perez C, Anesini C, **“Inhibition of *Pseudomonas aeruginosa* by Argentinean medicinal plants”, *Fitoterapia*, 65(2), 1994, 169-172.**
90. Alkofahi A, Masaadeh H, Alikhalil S, **“Antimicrobial evaluation of some plant extracts of Traditional medicine of Jordan”, *Alex J pharm sci*, 10(2), 1996, 123-126.**
91. Tanaka T, Nonaka G.I, Nishioka I, **“Tannins and related compounds.C. Reaction of dehydro hexa hydroxyl diphenic acid esters with bases, and its application to the structure determination of pomegranate tannins, granatins a and b” *Chemical and Pharmaceutical Bulletin*, 38, 1990, 9424-9428**
92. Satomi H, Umemura K, Ueno A, Hatano, Okuda t, Noro T, **“Carbonic anhydrase inhibitors form the pericarps of *P. granatum* L.” *Biol Pharm Bull*, 16(8), 1993, 787-790.**
93. Dhawan B.N, Saxena P.N, **“Evaluation of some indigenous drugs for stimulant effect on the rat uterus. A preliminary report”. *Indian J Med Res*, 46(6), 1958, 303-311.**

94. Gujral M.L, Varma D.R, Sareen K.N, **“Oral contraceptives. Part I. Preliminary observations on the antifertility effect of some indigenous drugs”**, *Indian J Med Res*, 48, 1960, 46-51
95. Kim N.D, **“Anthelmintics in crude drugs on the drugs for Tape worms”**, *Yakhak Hoe Chi*, 19, 1974, 87.
96. Sato A, **“Chemotherapy with oriental medicine.I. Antitumor activity of crude drugs human tissue culture in invitro screening”**, *Intl J Orient Med*, 15(4), 1990, 171-183.
97. Hukkeri v.I, Kalyani G.A, Hatpaki B.C, Manvi F.V, **“Invitro anthelmintic activity of aqueous extract of fruit rind of *P.granatum*”**, *Fitoterapia*, 64(1), 1993, 69-70.
98. Khennouf S, Gharzouli K, Amira S, Gharzouli A, **“Effects of join *Quercus ilex* L. and *P.granatum* L. polyphenols against Ethanol-induced gastric damage in rats”**, *Pharmazie*, 54(1), 1999, 75-76.
99. Roos R.G, selvasubramanian S, Jayasundar S, **“Immuno modulatory activity of *P.granatum* in rabbits, A preliminary study”**, *J. Ethnopharmacol*, 78(1), 2001, 85-87
100. Murthy K.N.C, Jayaprakasha G.K, Singh R.P, **“Studies on antioxidant activity of Pomegranate (*P.granatum*) peel extract using invivo models”**, *Journal of Agri Food Chem*, 50(17), 2002, 4791-4795
101. Aslan M, Sezik E, Yesilada E, **“Hypoglycemic and antidiabetic effect of *P. granatum* L. fruit in normal and alloxan – induced diabetic rats”**, *Journal of faculty of Pharmacy of Gazi University*, 20 (1), 2003, 9 – 14.

102. Bafna P, Bodhankar S, **“Gastro intestinal effects of Mebarid, an ayurvedic formulation, in experimental animals”**, *J Ethnopharmacol*, 56, 2003, 173 – 176.
103. Ajaykumar K.B, Asheef M, Babu B.H, Padikkala J, **“The inhibition of gastric mucosal injury by *P. granatum* L. (Pomegranate) methanolic extract”**, *J Ethnopharmacol*, 96, 2005, 171 – 176.
104. Qnais K.Y, Elokda A.s, Ghalyun A.Y.Y, Abdulla F.A, **“Antidiarrhoeal activity of the aqueous extract of *P. granatum* (Pomegranate) peels”**, *Pharmaceutical Biol*, 45 (9), 2007, 715 – 720.
105. Sestili P, Martinelli C, Ricci D, Fraternale D, Bucchimi A, Giamperi L, Curcio R, Piccoli G, Stocchi V, **“Cytoprotective effect of preparations from various parts of *P. granatum* L. fruits in oxidatively injured mammalian cells in comparison with their antioxidant capacity in cell free systems”**, *Pharmacological Research*, 56, 2007, 18 – 26.
106. Naovi S.A.H, Khan M.S.Y, Vohora S.B, **“Antibacterial, Antifungal and anthelmintic investigations of Indian medicinal plants”**, *Fitoterapia*, 62 (3), 1991, 221 – 228.
107. Miranda D, Pereira L, Sirsat S.M, Antarkar D.S, Vaidya A.B, **“Invitro action of selected medicinal plants against microorganisms involved in human gastrointestinal infections”**, *J Research in ayurveda and Siddha*, 14 (3 – 4), 1993, 149 – 153.
108. Goto W, Kusumoto I.T, Kadota S, Namba T, Kurokawa M, Shiraki K, **“Suppression of Hepatitis–B virus surface antigen secretion by traditional plant medicine”**, *Phytother Res*, (10) 6, 1996, 504 – 507.

109. Prasanth D, Asha M.K, Amit A, “**Antibacterial activity of *P. granatum***”, *Fitoterapia*, 72 (2), 2001, 171 – 173.
110. Ahmed I, Aqil F, “**Anti – MRSA activity of certain Indian medicinal plants**”, *National symposium on Emerging trends in Indian medicinal plants, Lucknow*, 10 – 12, 2003, 13 – 14.
111. Arnason T, Uck F, Lambert J, Hebda R, “**Maya medicinal plants of San Jose succotz, Belize**”, *J Ethnopharmacol*, 2 (4), 1980, 345 – 364.
112. Ilham M, Yaday M, Norhanom A.W, “**Tumor promoting activity of plants used in Malaysian Traditional Medicine**”, *Nat Prod Sci*, 1 (1), 1995, 31 – 42.
113. Nadkarni K.M, “**The Indian Materia Medica**”, Vol-II, 1954, 1031-1035.
114. Elgamal M.H.A, Fayez M.B.E, “**Thin – layer chromatography of Triterpenoid acid**”, *Fresenius Journal of Analytical chemistry*, 211 (3), 1965, 190 – 194.
115. Fayez M.B.E, Negam S.A.R, Sharaf A, “**Pharmacological properties of *P. granatum***”, *Plant medica*, 11 (4), 1963, 439 – 443.
116. Robert M.F, Cromwell B.T, Webster D.E, “**The occurrence of 2 – (2-propenyl) – Beta – 1- Piperidine in the leaves of Pomegranate (*P. granatum L.*)**”, *Phytochemistry*, 6, 1967, 711 – 717.
117. Gawienowski A.M, Gibbs C.C, “**Biosynthesis of pregnenolone from cholesterol in *P. granatum***”, *Phytochemistry*, 8, 1969, 2317 – 2319.

118. Pavanasasivam G, sultan Bawa M.U.S, **“Betulinic acid in the Dilleniaceae and a review of its natural distribution”**, *Phytochemistry*, 13, 1974, 2002 – 2006.
119. Tawfik N.I, Tawil E.L., Bah, Refai E.L, Khalaf A.A, Khalil A.M, **“Constituents of local plants Part – I. Chemical investigation on some cultivated Saudi Arabian plants”**, *Qual Plant Foods Hum Nutr* 28(3), 1978, 203-210.
120. Tanaka T, Nonaka G.I, Nishioka I, **“Punicafolin, an Ellagitannin from leaves of *P. granatum* (I & B)”**, *Phytochemistry*, 24 (9), 1985, 2075 – 2078.
121. Nawwar M.A.M, Hussein S.A.M, Mefort I, **“NMR spectral analysis of polyphenols from *P. granatum*”**, *Phytochemistry*, 36 (3), 1994, 793 – 798.
122. Nawwar M.A.M, Hussein S.A.M, Merfort I, **“Leaf phenolics of *P. granatum*”**, *Phytochemistry*, 37 (4), 1994, 175 – 177.
123. Lei F.X.N. Zhang, W. Wang, D.M, Xing, W.D, Xie, H. Su, Du, L.J. **“Pomegranate leaf extract may be novel appetite suppressant”**  
<http://www.nutraingredients.com/europe>, *International Journal of obesity*, <http://www.naturalnews.com>.
124. Collier W.A, Piji L.V.D, **“The antibiotic action of plants, especially the higher plants, with results with Indonesian Plants”**, *Chron Nat* 105, 1949, 8.
125. Misas C.A.J, Hernadez N.M.R, Abraham A.M.L, **“Contribution to the Biological Evaluation of Cuban Plants IV”**, *Rev Cub Med Trop*, 31 (1), 1979, 29 – 35.

126. Ayudhaya T.D, Nutakul W, Khunanek U, Bhunsith J, Pawanunth K, Webster H.K, **“Study on the vitro antimalarial activity of some medicinal plants against *Plasmodium falciparum*”** *Bull Dept Med Sei* 29, 1987, 22-38.
127. Alkofahi A, Batshoun R, Owais W, Najib W, **“Biological activity of some Jordanian medicinal plant extracts, Part II”**, *Fitoterapia* 68(2), 1997, 163-168.
128. Heftmann E, Ko S.T, Bennat R.D, **“Identification of estrone in pomegranate seeds”**, *Phytochemistry*, 5, 1996, 1337.
129. Ahmed R, Ifzal s.M, Saifudin A, Nazeer M, **“Studies on *P.granatum*. I. Isolation and identification of some constituents from the seeds of *P. granatum*”**, *Pakistan J Pharmaceutical sciences*, 8, 1995, 65 – 71.
130. Schubert S.Y, Lansky E.P, Neeman I, **“Antioxidant and eicosanoid enzyme inhibition properties of Pomegranate seed oil and fermented juice flavonoids”**, *J Ethnopharmacol*, 66, 1999, 11 – 17.
131. Dean P.D.G, Exley D, Goodwin T.W, **“Steroid oestrogens in plants Re-estimation of Oestrone in Pomegranate seeds”**, *Phytochemistry*, 10, 1971, 2215.
132. Lee, J.W, Choi, J.H, Kang S.M, **“Screening of medicinal plants having Hepatoprotective activity effect with primary cultured, Hepatocytes intoxicated using carbon tetrachloride Cytotoxicity”**, *Korean J Pharmacog*, 23 (4), 1992, 268 – 275.
133. Abdul El Wahab, Elfiki N.M, Mostafa S.F, Hassan A.E.B, **“Characterization of certain steroid hormones in *P. granatum* L. seeds”**, *Bulletin of the faculty of Pharmacy*, 36, 1998, 11 – 15.

134. Das A.K, Mardalk S.C, Banerjee S.K, Sinha S, Das J, Saha B.P, Palm M, **“Studies on antidiarrhoeal activity of *P. granatum* seed extract in rats”**, *J Ethnopharmacol*, 68 (1/3), 1999, 205 – 208.
135. Selvsubramanian S, Ruthsophila J, Jayasunder S, **“Studies on the antinematodal effect of Pomegranate seed preparation”**, Proceedings of International congress on, *Ayurveda*, 2000, Chennai, 2000, Jan 28 – 30, 206 – 207.
136. Kwak H.M, Jeon S.Y, Sohng B.H, Kim J.G, Lee J.M, Lee K.B, Jeong H.H, Hur J.M, Kang Y.H, Song K.S, **“ $\beta$  – secretase (BACE) inhibitors from Pomegranate (*P. granatum*) husk”**, *Arch Pharm Res*, 28 (12), 2005, 1328 – 1332.
137. Singh V.P, Sharma S.K, Khare V.S, **“Medicinal plants from Ujjain district Madya Pradesh – Part II”**, *Indian drugs Pharm Ind*, 5, 1980, 7 – 12.
138. Bharadwaj S, Gakhar S.K, **“Ethnomedicinal plants used by the tribals of Mizoram to cure dysentery”**, *Ethnobotany*, 15 (1 – 2), 2003, 51 – 54.
139. Neuhofer H, Writte L, Gorunovic M, Czygan F.C, **“Alkaloids in the bark of *P.granatum* L. (Pomegranate) from Yugoslavia”**, *Pharmazie*, 48, 1993, 389 – 391.
140. Chauhan D, Chauhan J.S, **“Flavonoid diglycoside from *P.granatum*”**, *Pharmaceutical Biology*, 39 (2), 2001, 155 – 157.
141. Tripathi S.M, Singh V.K, Singh S, Singh D.K, **“Enzyme inhibition by the Molluscicidal agent *P. granatum* Linn. Bark and *Canna indica* Linn. Root”**, *Phytother Res*, 18, 2004, 501 – 506.

142. Caius J.F, Mhaskar K.S, **“The correlation between the chemical composition of anthelmintic and their therapeutic value in connection with the Hook worm injury in the Madras presidency XXI, Miscellaneous Anthelmintics”**, *Indian J Med Res*, 11, 1923, 353 – 370.
143. Yazicioglu A, Tuzlaci E, **“Folk medicinal plants of Trabzon (Turkey)”**, *Fititerapia*, 67 (4), 1996, 307 – 318.
144. Sousa P.D.M, Rougnayrol M.Z, **“Mollucicidal activity of plants from Northeast Brazil”**, *Rev Brasil Pesq Med Bio*, 7 (4), 1974, 389 – 394.
145. Singhal K.C, **“Anthelmintic activity of *P.granatum* and artemisia silversiana against experimental infections in mice”**, *Indian J Pharmacol*, 15 (2), 1984, 119 – 122.
146. Desta A.B, Ethiopian **“Traditional herbal drugs, Part I : Studies on the toxicity and Therapeutic activity of local Technical medication”**, *J Ethnopharmacol*, 45 (1), 1995, 27 – 33.
147. Kurokawa M, Ochiah H, Nagasaka K, Neki M, Xu H.X, Kadota S, Nmba T, Sutardio S, Matsumoto T, Shiraki K, **“Anti viral traditional medicines against herpes simplex virus (HSV – 1), Polyvirus and measles virus invitro and their therapeutic efficacies for HSV – 1 infection in mice”**, *Antiviral Res*, 22 (2/3), 1993, 175 – 188.
148. Michael, A.S., Thompson C.G. and Abramovitz M. **“Artemia Salina as a test Organism for a bioassay”**, *Science*; 1956; 123, 464.
149. Vanhaecke P., Persoone, G., Claus C., Sorgeloos P., **“Proposal for a short – term toxicity test with Artemia nauplii Ecotoxicologyl and Environmental safety”**, 5; 1981, 382-87.



150. Sleet R.B., Brendel K., **“Improved Methods for harvesting and counting synchronous populations of *Artemia nauplii* for use in developmental toxicology”**, *Ecotoxicology and Environmental safety*, 7; 1983; 435- 446.
151. Sadhana sathaye, Dr. Juvekar AR., Dr. Kulkarni R.D., **“Rapid method for screening bioactivity / toxicity of Herbal preparations”**, *Indian drugs*; 38 (11); Nov 2001; 569-72.
152. Sung S.H, Kang S.Y, Lee K.Y, Park M.J Kim J.H, Park J.H, Kim Y.C, Kim J, **“(+) -  $\alpha$  - Viniferin, a stilbene Trimer from *carangana chamlaque*, inhibits acetylcholinesterase”** *Bio Pharm Bull* 25(1) 2002, 125-127.
153. Gupta S.K, **“Drug screening methods”** 1st edn, New Delhi, Jay Pee Brothers Medical Publishers (P) Ltd, 2004, 117-121.
154. Adsersen A Kjolbye A, Dall O, Jager A.K, **“Acetylcholinesterase and Butylcholinesterase inhibitory compounds from *corydalis cava schweigg. & Kort*”**, *J Ethnopharmacol* 113, 2007, 179-182.
155. Variar P.S (Vaidyaratnam) **“Indian Medicinal plants”** a Compendium of 500 species Vol – IV Kottakkal Arya Vaidya Sala, Orient Longmann Limited 1995, 396 – 402.
156. Murukesa mudaliar P.S **“Siddha materia medica”** (Gunapadam) 7<sup>th</sup> edn, Chennai, Thiruvallur MLMP Publications, 2003, 749 – 753.
157. Dr. Duke’s Phytochemical and Ethnobotanical data base.  
<http://www.ars-grin.gov/duke>.
158. <http://www.enwikipedia.org/pomegranate>
159. Chopra R.N, Nayar S.L, Chopra I.C. **“Glossary of Indian medicinal plants”**, New Delhi, CSIR, 1956, 207.

160. **The Ayurvedic Pharmacopoeia of India** Vol – II, 1<sup>st</sup> edn, Part – I, New Delhi, Government of India Publication, 1999, 31 – 32.
161. K.R. Kirtikar, B.D. Basu, **“Indian medicinal plants”** Vol – II 2<sup>nd</sup> edn, published by Lalit Mohan Basu, M.B, 49, Leader Road Allahabad, India.
162. Dastur J.F **“Useful Plants of India and Pakistan”**, 1<sup>st</sup> edn, Bombay, D.B.T & Co, 175.
163. Anonymous, **“Homoeopathic pharmacopoeia of India”**, Ministry of Health and family welfare; vol. 6, 1990, 24.
164. Wallis. T.E., **“Practical Pharmacognosy”**, 6<sup>th</sup> edn, London; J & A Church Limited, 1955; 139 – 140, 173 – 74.
165. Kokate, C.K., **“Practical Pharmacognosy”**, 4<sup>th</sup> edn; Delhi, Vallabh Prakashan; 1994; 7 – 9; 14 – 20.
166. Johansen D.A **“Plant microtechnique”**, New york Mc Graw Hill Book Co, 1940, 523.
167. Wallis. T.E. **“Text book of Pharmacognosy”**, 5<sup>th</sup> edn, Delhi; CBS Publishers and Distributors; 1997; 111 – 117; 561 – 562.
168. Kokate C.K, Purohit A.P, Gokhale S.B, **“Pharmacognosy”**; 32<sup>nd</sup> edn; Pune; Nirali Praksahan; 2005; 99 – 100; 111 – 112.
169. Anonymous, **“The Ayurvedic Pharamcopoeia of India”**, 1<sup>st</sup> edn; New Delhi; Ministry of Health and family welfare, Department of Indian system of medicine and Homoeopathy, Part – I, Vol. II, 1<sup>st</sup> edn; 1999, 183 – 196.
170. Kokate, C.K, **“Practical pharmacognosy”**, 4<sup>th</sup> edn; Delhi, Vallabh Prakashan; 1994; 117 – 119, 123 – 125.

171. Anonymous, **“Indian Pharmacopoeia”**, Delhi; Ministry of Health and Family Welfare; Vol. 11, 1996; A – 53, 54, 89.
172. Muherjee P.K, **“Quality control of Herbal drugs”**, An approach to evaluation of botanicals; 1<sup>st</sup> edn, Business Horizons Pharmaceutical Publisher; 2002; 186 – 190.
173. Wagner H, Bladt S, **“Plant Drug Analysis”**, A Thin layer chromatography Atlas; 2<sup>nd</sup> edn; Springer; 1996; 3 – 6 & 308.
174. Finar I.L, **“Organic Chemistry”**, 4<sup>th</sup> edn; London; ELBS : Vol. 11; 1989; 518.
175. Harbone J.B, **“Phytochemical analysis – A guide to modern techniques of plant analysis”**, Chapman & Hall, London.
176. Kokate C.K, Purohit A.P, Gohale S.B, **“Pharmacognosy”**, Nirali Prakashan, Pune, 32<sup>nd</sup> edn, 2005; 106 – 109, 271 – 271, 593 – 597.
177. Kurt Randerath, **“Thin layer chromatography”**, New York, Verlag Chemie Academy Press; 2<sup>nd</sup> edn. 1966.
178. Bobbit J.M, **“Thin Layer Chromatography”**, New York, Reinhold Publishing Corporation 1966.
179. Chatwal GR, Anand S.K, **“Instrumental methods of chemical Analysis”**, 5<sup>th</sup> edn, Mumbai, Himalaya Publishing House, 2005, 2.625 – 2.626, 2.630 – 2.631.